CLINICAL STUDY PROTOCOL  
A PHASE 1, RANDOMIZED, PLACEBO -CON TR OLLED, 
DOSE -RANGING STUDY TO EV ALUATE THE SAFETY AND 
IMMUNOGENICITY OF mRNA -1325  ZIKA V ACCINE IN HEALTHY 
ADULTS IN A NON-ENDEMIC ZIKA REGION 
PROTOCOL NO. mRNA-1325-P10 1 
Sponsor:  Moderna Therapeutics, Inc.  
200 Technology Square  
Cambridge, MA 021 39  
Sponsor Contact:  
 
M
oderna Therapeutics, Inc.  
 200 Technology Square  
Cambridge, MA 02139  
Telephone:  
Version of Protocol:  Final  6.0 
Date of Protocol:  13 August 2018  
CONFIDENT
IAL 
The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed, 
written consent of Moderna Therapeutics, Inc. 
The study will be conducted a ccording to the International Council for Harmonisation 
harmonised tripartite guideline E6(R1): Good Clinical Practice.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0NCT # : NCT030 14089
PPD
PPD
Document Number: VV-CLIN-000234 eDMS Version: 2.0
PPD
PPD
PPD
PPD
PPD
PPD
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 3 Investigator Protocol Agreement Page  
 
I agree to conduct the study as outlined in the protocol entitled “A Phase 1 Randomized, 
Placebo -Controlled, Dose -Ranging Study to Evaluate the Safety and Immunogenicity of 
mRNA-1325 Zika Vaccine in Healthy Adults  in a N on-endemic Zika Region ” in accordance 
with the guidelines and all applicable government regulations including US Title 21 of the 
Code of Federal Regulations Part  54. I  have read and understand all sections of the protocol. 
   
Signature of Investigator   Date  
   
Printed Name of Investigator    
 
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 4 Table of Contents  
Signature Page .......................................................................................................................... 2  
Investigator Protocol Agreement Page...................................................................................... 3  
Table of Contents ...................................................................................................................... 4  
List of Tabl es ............................................................................................................................. 7  
List of Figures  ........................................................................................................................... 7  
Protocol Synopsis...................................................................................................................... 8  
List of Abbreviations ............................................................................................................... 23  
1 Introduction .................................................................................................................... 25  
1.1 Background ............................................................................................................25  
1.2 Non-clinical Studies in Development of mRNA -1325 ..........................................26  
1.2.1  Non-clinical Pharmacology  ......................................................................26  
1.2.2  Distribution  ...............................................................................................27  
1.2.3  Toxicology ................................................................................................27  
1.2.4  Genotoxicity .............................................................................................28  
1.3 Clinical Studies with mRNA -1325 ........................................................................28  
1.4 Rationale for Study ................................................................................................29  
1.5 Rationale for Dose Selection  .................................................................................29  
1.6 Rationale for Study Design  ....................................................................................30  
2 Study Objectives  ............................................................................................................. 32  
2.1 Primar y Objective  ..................................................................................................32  
2.2 Secondary Objective  ..............................................................................................32  
2.3 Exploratory Objective ............................................................................................32  
3 Investigational Plan  ........................................................................................................ 33  
3.1 Study Design  ..........................................................................................................33  
3.2 Selection of Study Population ................................................................................38  
3.2.1  Inclusion Criteria  ......................................................................................38  
3.2.2  Exclusion Criteria  .....................................................................................40  
3.2.3  Subject Restrictions During the Study  ......................................................43  
3.3 Withdrawal of Subjects From the Study ................................................................44  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 5 3.3.1  Reasons for Withdrawal  ............................................................................44  
3.3.2  Handling of Withdrawals  ..........................................................................45  
3.3.3  Replacements  ............................................................................................45  
3.4 Study Treatments  ...................................................................................................46  
3.4.1  Method of Assigning Subjects to Treatment Groups ................................46  
3.4.2  Treatments Administered  ..........................................................................46  
3.4.3  Identity of Investigational Product ...........................................................49  
3.4.4  Management of Clinical Supplies  .............................................................50  
3.4.5  Blinding ....................................................................................................51  
3.4.6  Breaking the Blind  ....................................................................................52  
3.4.7  Treatment Compliance  ..............................................................................52  
3.4.8  Prior and Concomitant Medications .........................................................53  
3.5 Study Procedures  ...................................................................................................54  
3.5.1  Safety Contact  ...........................................................................................55  
3.5.2  Completion of Memory Aid  ......................................................................56  
3.5.3  Immunogenicity Assessments  ...................................................................56  
3.5.4  Total Blood V olume  ..................................................................................57  
3.5.5  Safety Assessments  ...................................................................................58  
3.5.6  Solicited Safety Measurements  .................................................................58  
3.5.7  Unsolicited Safety Measurements  ............................................................60  
3.5.8  Clinical Laboratory Testing  ......................................................................65  
3.5.9  Vital Sign Measurements  ..........................................................................67  
3.5.10  Physical Examinations  ..............................................................................68  
3.6 Statistical Analysis Plans  .......................................................................................68  
3.6.1  Safety Endpoints  .......................................................................................68  
3.6.2  Immunogenicity Endpoints .......................................................................69  
3.6.3  Sample Size Calculations  .........................................................................70  
3.6.4  Analysis Sets  .............................................................................................70  
3.6.5  Statistical Analysis  ....................................................................................71  
3.6.6  Handling of Missing Data .........................................................................73  
3.6.7  Interim Analyses  .......................................................................................73  
3.7 Data Quality Assurance ..........................................................................................74  
4 Investigator Obligations ................................................................................................. 75  
4.1 Confidentiality  .......................................................................................................75  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 6 4.2 Institutional Review  ...............................................................................................75  
4.3 Subject Consent .....................................................................................................76  
4.4 Study Reporting Requirements ..............................................................................76  
4.5 Financial Disclosure and Obligations ....................................................................76  
4.6 Investigator Documentation ...................................................................................77  
4.7 Study Conduct ........................................................................................................77  
4.8 Data Collection  ......................................................................................................78  
4.8.1  Case Report Forms and Source Documents .............................................78  
4.9 Adherence to Protocol............................................................................................78  
4.10  Reporting Adverse Events ......................................................................................78  
4.11  Investigator’s Final Report ....................................................................................79  
4.12  Records Retention  ..................................................................................................79  
4.13  Publications ............................................................................................................79  
5 Study Management ......................................................................................................... 80  
5.1 Monitoring .............................................................................................................80  
5.1.1  Monitoring of the Study............................................................................80  
5.1.2  Inspection of Records ...............................................................................80  
5.2 Management of Protocol Amendments and Deviations.........................................80  
5.2.1  Modification of the Protocol .....................................................................80  
5.2.2  Protocol Violations and Deviations ..........................................................81  
5.3 Study Termination  ..................................................................................................81  
5.4 Final Report ...........................................................................................................82  
6 Appendices ..................................................................................................................... 83  
6.1 Appendix 1: Schedules of Events ..........................................................................83  
6.2 Appendix 2: Adverse Events of Special Interest ....................................................90  
6.3 Appendix 3: Toxicity Grading Scale Tables ..........................................................94  
6.4 Appendix 4: World Health Organization Zika Situation Report as of February 
2017......................................................................................................................100  
7 Reference List  ............................................................................................................... 103  
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 7 List of Tables  
Table  1-1  Summary of Non- clinical Studies of mRNA -1325 ......................................... 26  
Table  3-1  Total Blood V olume  ........................................................................................ 57  
Table  6-1  Part A: Schedule of Events  ............................................................................. 84  
Table  6-2  Part B: Schedule of Events ............................................................................. 89  
Table  6-3  Tables for Clinical Abnormalities  ................................................................... 94  
Table  6-4  Tables for Laboratory Abnormalities  .............................................................. 97  
List of Figures  
Figure 3 -1 Cohort and Treatment Assignment .................................................................. 34  
Figure 3 -2 Dosing Schema by Cohort .............................................................................. 35  
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 8 Protocol Synopsis  
Protocol  Number:  mRNA -1325 -P101  
Title:  A Phase 1, Randomized, Placebo- Controlled, Dose -Ranging Study to 
Evaluate the Safety and Immunogenicity of mRNA -1325 Zika Vaccine 
in Healthy Adults in a Non -endemic Zika Region 
Study Phase:  1 
Study Sites:  At least 2 sites in the United States or its territories  
Objectives:  Primary:  
• To assess the safety of a 2 -dose vaccination schedule of 
mRNA- 1325 Zika vaccine, given 28 days apart, across a range 
of dose levels in flavivirus -seronegative and 
flavivirus-seropositive subjects compared with  placebo. 
Secondary:  
• To assess the immunogenicity of a range of doses of 
mRNA- 1325 Zika vaccine and to select  a dose to move 
forward into further development, based on changes from 
Baseline in the following tests: 
• Zika virus (ZikaV) -specific neutralizing antibody titer s 
measured by a Plaque Reduction Neutralizing Titer  EC50 
(PRNT50); 
Exploratory: 
• ZikaV antigen- specific stimulation of T cells measured by 
interferon gamma (IFN γ) enzyme -linked ImmunoSpot 
(ELISPOT) on subject -derived peripheral blood mononuclear 
cells (PBMCs) , if results of interim immunogenicity analys es 
warrant further analyses of samples.  
• To assess the impact of mRNA -1325 Zika vaccine on a range 
of other functional and diagnostic flavivirus assays. 
Study Design and 
Methodology: This is a Phase 1, double -blind, placebo- controlled, dose -finding study 
to evaluate the safety and immunogenicity of  a range of dose levels o f 
mRNA- 1325 Zika vaccine given in a 2-dose vaccination schedule, 
28 days apart, and compared with  placebo  in healthy adult subjects 
(18 to 49 years of age, i nclusive). mRNA -1325 is an mRNA -based 
vaccine candidate being tested for its ability to safely indu ce an 
immune response expected to be able to prevent ZikaV infection. 
ZikaV is a single -stranded  RNA flavivirus, which is transmitted to 
humans by a mosquito vector (mainly Aedes aegypti  but other Aedes  
mosquitoes are believed to be competent vectors) or by 
person -to-person spread, mainly through sexual transmission. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 9 Currently there is no vaccine to protect against this disease, which has 
spread rapidly from Asia to most tropical and subtropical regions 
including the Americas.  
This is a 2 -part study. Part  A includes dose -finding, safety, and 
immune testing through 28 days following the second vaccination. 
Once subjects complete the final visit in Part  A, they will be entered 
into Part  B. Part  B is a blind ed follow -up period with assessment of 
safety through 12 mont hs and immune persistence at 168 (±15) days 
and 364 (+15) days following the second vaccination in Part  A. 
Immune persistence at 168 days and 364 days will be evaluated if 
interim immunogenicity analyses  warrants long term analyses of 
persistence.  
Part A  
Subjects will be randomly assigned in a blinded fashion in a n 
approximate 4:1 ratio to receive mRNA-1325 or placebo at 1 of 3 dose 
levels ( 10 µg, 25 µg, or 100 µg), with each subject receiving 
2 vaccinations separated by 28  (+7)  days. Dosing will begin with 
10 µg (Cohort  2), followed by 25 µg (Cohort  3), and then 100 µg 
(Cohort 4). There will be no Cohort 1 included in this study. 
Approximately t wo-thirds of the enrolled subjects at each dose le vel 
will be flavivirus naïve and approximately one-third will be flavivirus 
seropositive as a result of having received a yellow fever vaccination 
in the past 20 years by either: a) military assignment in the previous 
20 years that requires a yellow fever vaccination; or 2) yellow fever 
vaccination documented on an international certificate or other 
confirmatory documentation of yellow fever vaccination. 
Cohort and Treatment Assignment  
Cohort  Flavivirus 
Status  Treatment Assignment  
(µg mRNA -1325 or placebo ) Total  
(Ratio)  
2 + 10 
30 
(4:1)  - 10 
+ placebo  
- placebo  
3 + 25 
30 
(4:1)  - 25 
+ placebo  
- placebo  
4 + 100 
30 
(4:1)  - 100 
+ placebo  
- placebo  
 
Abbreviations: +, flavivirus seropositive; -, flavivirus seronegative.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 10  For each cohort , a sentinel safety group  will enroll  
3 flavivirus- seronegative subjects randomized to mRNA -1325 and 
followed for 7 days after first vaccination, with review of 
reactogenicity (Section 3.5.6) and safety laboratory results, prior to 
randomizing the remainder of the cohort. An internal safety team 
(IST) will oversee the safety of the trial and will review blinded safety 
data during Part A of the study to ensure  adherence to the protocol, 
monitor safety laboratory  test results  and reactogenicity , and raise 
concerns to the Safety Monitoring Committee (SMC) should there be safety issues or operational challenges that could affect subject safety. Only after review b
y the IST of the blinded safety data 
(reactogenicity, safety labs , and AEs) through 7 days following first 
vaccination of the sentinel safety lead -in for each cohort planned will 
approval be given to allow randomization of the remainder of that cohort. The SMC will approve escalation to the next higher dosing 
cohort after review of blinded safet y data of the currently dosed  
cohort through 7 days following the second vaccination and any cumulative safety data of all cohorts as the trial advances. The SMC will also be convened (ad hoc meeting) if a pause rule is triggered.  
Dosing Schema by Cohort 
 
Abbreviations: D, day; Plc, placebo; SMC, safety monitoring committee.  
Note: Yellow shading depicts safety follow -up of the first vaccination period and grey shading 
depicts safety follow -up of the second vaccination period for cohorts by dose sequence.  
Note : The SMC will approve escalation to the next higher dosing cohort after review of 
blinded safety data of the currently dosed cohort through 7 days following the second 
vaccination and any cumulative safety data of all cohorts as the trial advances.  
The v accine will be administered as an intramuscular (IM) injection 
(0.5 mL) into the deltoid muscle as a 2 -dose vaccination schedule at 
Visits  1 and 4 (at least a 28 -day interval between dosing). The second 
dose of study drug will be administered preferably in the same arm 
used for the first dose. Vaccine accountability, dose preparation, and 
vaccine administration will be performed by unblinded pharmacy 
personnel , who will not participate in any other aspect of the study. 
The remainder of the site staff and all subjects will remain blinded to treatment assignment.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 11 Screening and consent will occur over a 28- day period before 
randomization ( West N ile virus ser ology screen can occur up to 
90 days prior to randomization). A total of 30 subjects for each dos e 
cohort will be assigned, 24 subjects to mRNA -1325 and 6 subjects to 
placebo ( approximate 4:1 ratio overall). The first 3 subjects for each 
dose level will be rando mized to mRNA -1325. Subjects who me et all 
eligibility criteria  will receive the first vaccination at Visit 1. Of note, 
a subject who has met all eligibility criteria but is noted to have a blood 
pressure, heart rate or respiratory rate that is Grade 2 or greater (even after relaxing/resting) in the clinic on the day of vaccination should not receive a vaccination on that day and will need to return on a subsequent day for their vaccination. Similarly, if a subject has a fever 
(>37.9°C ) or an in tercurrent illness , vaccination should be withheld 
until resolved (as specified in exclusion criterion 20). Each subject will 
be monitored in the clinic for at least 1  hour following vaccination to 
assess for immediate reactogenicity, with vital sign measurements and  
local and systemic reactogenicity toxicity scored at that time . The 
highest toxicity recording will be entered into the electronic case 
report form.  
Subjects will be instructed on recording reactogenicity, adverse events (AEs), and medications (prescription or over -the-
counter) on the 
memory aid (ie, diary card), and will be provided measuring tools, and instructed to call or return to the clinic within 24  
hours if a 
reactogenicity score reaches Grade 3 or greater during the first 7  days 
following vaccinat ion. As standard practice, a reminder call will be 
made to the subject by the site at least once during the first 7  days 
following each vaccination to answer any questions and ensure that the memory aid is being completed correctly  and consistently . All 
subjects will return on 7  (+3) (cellular  PBMC testing ) and 28 (+7) 
(humoral neutralization testing ) days following each vaccination for 
safety assessments and blood sampling for immune testing. 
Safety assessments will include monitoring and recording of soli cited 
(local and systemic reactogenicity) events (first 7 days after each 
vaccination); clinical laboratory test results including hematology, 
serum chemistry, coagulation, and urinalysis; vital sign measurements; 
and physical examination findings ( Day 7 after each vaccination) and 
unsolicited AEs (throughout Part  A). All unsolicited AEs and 
concomitant medication (including over the counter) usage will be 
collected.  Specific categories of safety data collected will include  
serious adverse events (SAEs), AEs of special interest (AESIs),  AEs 
leading to study withdrawal, and medically attended AEs. At clinic 
visits, the investigator will review, confirm, and grade the 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 12 reactogenicity recorded in the memory aid and inquire about and 
review AEs and medications.  
All safety laboratory tests will be performed according to Table  6-1. 
Safety laboratory tests will be performed during Screening (to allow 
for assessm ent of inclusion and exclusion criteria), on the day of first 
vaccination  (Visit 1) , 7 (+3) days following each vaccination (Visit 2 
and Visit  5), and 28 (+7) days following each vaccination (Visit 4 
[prior to second vaccination] and Visit  7). At 17  (±3) days following 
each vaccination  (Visit 3 and Visit 6) and at 21 ( +3) days after the first 
vaccination (Visit 3a) for the sentinel  subjects , a subset of safety 
laboratory tests will be performed as specified in Table  6-1. Blood test 
results  (pre-vaccination)  at Visit 1 will be the basis for evaluation of 
changes from Baseline after vaccination.  
Blood samples for immunogenicity assessments (cellular and 
humora l) will be collected the day of vaccination (before vaccination) 
and 7 (+3)  and 28 (+7) days , respectively,  following each vaccination. 
Subjects that miss the second vaccination due to noncompliance with the visit schedule and not due to a cohort pause will still be required 
to follow the original visit and testing schedule. These subjects will be 
asked to  undergo blood collection to comply with a second immune 
test at Visit 7 ( 56+7 days after first vaccination ). 
To allow cohort advancement, the f
ollowing data from the highest 
dosed cohort is expected to be reviewed by the SMC: 1)  toxicity 
scoring of safety laboratory test results through 7  days following the 
second vaccination (through Visit 5); 2) toxicity scoring of vital signs 
and reactogenicit y through 7 days following the first and second 
vaccination (through Visit  5); 3) all unsolicited AEs (with grading and 
relatedness ). Data will be prepared  by dose categor y and timing 
relative to the last vaccination. As safety data on all cohorts 
accumulate, the SMC will also  review ongoing AEs as well as 
cumulative safety laboratory test results, reactogenicity, and AEs 
across vaccine doses for  subjects remain ing in Part  A of the study, 
thereby providing a cumulative and comprehensive review of safety. Should a cohort pause occur due to pre -specified criteria, the SMC will 
be convened for an unscheduled (ad hoc) meeting and be provided with specific safety data related to the trigger of the pause.  
Part A is concluded for each subject at  the time when they return to the 
clinic for Visit 7 (28 days following the second vaccination). At that 
time, a subject will be entered into Part B of the study. Once query resolution and immune testing is completed for each cohort in Part A, the database will be locked. Results will be provided to the Sponsor, 
SMC, and IST. The Sponsor may determine whether dosing 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 13 adjustments are required  during the conduct of the study based on 
either safety or immune responses per cohort. As dose escalation 
occurs, cumulative analyses will be included for each subsequent data 
lock to allow for all prior dosing cohorts to be analyzed by cohort, treatment assignment, and in aggregate for mRNA -
1325 exposure. 
Subject -level individual treatment assignment will not be released  to 
the subjects or to those individuals involved in manag ing or assessing 
safety in Part  B of the study until that portion of the study is completed. 
 Part B  – 12 Month Follow-u p After Final Vaccination  
To monitor for longer -term safety and immune persistence, each 
subject will be entered into a continued blinded follow -up period 
(Part  B). This period will be conducted such that subjects, observers, 
and safety monitors will remain blinded to treatment assignment. 
Part B of the study is initiated for  a subject once they have returned for 
Visit 7 (28 days following the second vaccination). The safety 
database utilized for Part  B may be accessed by the pharmacovigilance 
safety team for safety signal detection at scheduled intervals for 
ongoing assessmen ts for a given vaccine candidate as well as for the 
mRNA platform technology.  
Once entered into Part  B, each safety contact will occur by 
telemedicine (eg, telephone, text  message, internet) every 
28 (±7) days, and blood samples for immune persistence will  be 
collected from each subject at 168 (±15) days and 364 (+15) days 
following the second vaccination. Immune persistence at 168 days and 
364 days will be evaluated if interim immunogenicity analyses  
warrants long term analyses of persistence.  Each safety contact will 
capture outcomes of any AESI or SAE that remains unresolved since 
the last visit or is newly identified through scripted query. The 
telemedicine visits may require a dditional data through medically 
attended visits, in addition to medications and vaccination taken by the subject during this time . Subjects will have consented during study 
enrollment to allow access to additional medical records needed to complete Part  
B, thereby allowing the blinding of the treatment 
assignment to be maintained.  
When all subjects have completed their final contact (approximately 12 months after their last vaccination), immune testing is completed, and all queries resolved, the database will be locked and analyzed with a final  clinical study  report pro vided to regulators. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 14 Inclusion Criteria:  Each subject must meet all of the following criteria during the 
screening period to be enrolled in this study: 
1. The subject is male or female between 18 and 4 9 years of age, 
inclusive. 
2. The subject has a body mass index between 18 and 35 kg/m2, 
inclusive.  
3. The subject is considered by the investigator to be in good general 
health as determined by medical history.  
4. Female subjects must be non- pregnant and non- lactating and meet 
one of the following criteria: a) post -menopa usal (defined as 
12 consecutive months with no menses without an alternative 
medical cause or documented plasma follicle -stimulating hormone 
level in the post -menopausal range); b)  surgically sterile 
(ie, hysterectomy, bilateral tubal ligation, or bila teral 
oophorectomy). NOTE: these procedures and laboratory test results must be confirmed 
by physical examination or official 
written confirmation of a procedure ; c) if of childbearing potential 
(defined as any female who has experienced menarche and who i s 
NOT permanently sterile or post -menopausal ), agrees to be 
heterosexually inactive from at least 21  days prior to enrollment 
and through 3 months after the final vaccination or agrees to 
consistently use any of the following methods of contraception from at least 21 days prior to enrollment and through 3 months 
after the final vaccination: condoms (male or female) with 
spermicide, diaphragm with spermicide, cervical cap with 
spermicide, intrauterine device, oral or patch contraceptives, 
Norplant®, Depo- Provera®, or other Food and Drug 
Administration (FDA) -approved contraceptive method that is 
designe d to protect against pregnancy . Periodic abstinence (eg, 
calendar, ovulation, symptothermal, post -ovulation methods) and 
withdrawal are not acceptable methods o f contraception. Male 
subjects must use an acceptable method of birth control (see 
above) and must also agree to refrain from donation of sperm from 
the time of first vaccination until 3 months following the last 
vaccination. Periodic abstinence, declaration of abstinence for the duration of the study, and withdrawal are not acceptable methods of contraception.  
5. Subject assigned to the flavivirus seropositive group has received a yellow fever vaccination in the past 20 years by either: a) military 
assignment in the previous 20 years that requires a yellow fever 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 15 vaccination; or 2) yellow fever vaccination documented on an 
international certificate or other confirmatory documentation. 
6. The subject understands and agrees to comply with the study 
procedures and  provides written informed consent. 
7. The subject has access to a consistent and reliable means of 
telephone contact, which may be in the home, workplace, or by 
personal mobile electronic device.  
8. The subject agrees to stay in contact with the study site for the duration of the study, to provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study.
 
Exclusion criteria:  Subjects meeting any of the following criteria will be exclud ed from 
the study: 
1. The subject has any ongoing significant chronic illness requiring 
medical or surgical care. Asymptomatic conditions or findings (eg, 
mild hypertension, dyslipidemia) that are not associated with 
evidence of end- organ damage are not exclusionary provided that 
they are being appropriately managed and are clinically stable in 
the opinion of the investigator (ie, unlikely to result in 
symptomatic illness within the time -course of this study).  
2. The subject has a history of active cancer (malig nancy) in the last 
10 years (e xception is subjects with adequately treated 
non-melanomatous skin carcinoma, who may participate in the 
study). 
3. The subject is a female of childbearing potential and has a positive pregnancy test at Screening or on the day of vaccination.  
4. The subject has abnormal liver enzyme tests  (increase in aspartate 
aminotransferase, alanine aminotransferase, or alkaline 
phosphatase) at Screening.  
5. The subject has received another investigational product in another investigational study within 60 days, or 5 half -lives, whichever is 
longer, before the planned date of first vaccination. 
6. 
The subject has received any live attenuated vaccines within 
4 weeks before enrollment or inactive vaccines within 2 weeks before enrollment, or plans to rece ive any vaccine during the activ e 
vaccination period (through 4 
weeks after their last planned 
vaccination).  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 16 7. The subject has received (at any time) a vaccine for Zika or dengue 
vaccine.  
8. The subject has a history of confirmed Zika or dengue infection.  
9. The subject has lived in or visited any Zika -endemic area (as 
defined by the World Health Organization [WHO ; Appendix 4]) 
greater than 4 weeks in duration (flavivirus -seronegative group, 
only). 
10. The subject has received any  vaccination for a flavivirus (eg , 
yellow fever, Japanese encephalitis) in his or her lifetime 
(flavivirus -seronegative group, only), or received a vaccination for 
a flavivirus more  than 20 years ago (flavivirus -seropositive group, 
only). 
11. The subject has a positive West Nile virus antibody titer above the 
detection level of the assay (flavivirus -seronegative group, only). 
NOTE: West Nile virus titer s are considered valid for a period of 
90 days (allowing for the screening period on West Nile virus to 
exceed the standard 28 days as noted for all other screening 
parameters ). 
12. The subject has reported previously participat ing in an 
investigational study involving lipid nanoparticles. 
13. The subject has a history of hypersensitivity or serious reactions (eg, anaphylaxis, urticaria, other significant reaction) to previous 
vaccinations.  
14. The subject has any known or suspected autoimmune disease or 
immunosuppressive condition, acquired or congenital, as 
determined by medical history and/or physical examination.  
15. The subject has a history of inflammator y arthritis.  
16. The subject has a neurologic disorder (eg, history of seizures, 
Guillain -Barré syndrome, dementia, vasculitis, or any known 
congenital or acquired disorder). 
17. The subject has a history of febrile disease with arthritis or 
arthralgia within 2 we eks of dose administration. 
18. The subject received immunoglobulins and/or any blood products within the 3 months preceding the administration of the study drug or plans to receive such products at any time during the study. 
19. The subject has had chronic administration (defined as more than 14 continuous days) of an immunosuppressant or other  
immune -modifying drug within 6  months before vaccine 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 17 administration or plans to receive any products during the active 
vaccination period (through 4 weeks after their last planned 
vaccination). An immunosuppressant dose of a glucocorticoid will be de fined as a systemic dose of ≥10  mg of prednisone per day or 
equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.   
20. The subject has any acute illness at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral  body temperature >3 7.9°C on the planned day of 
vaccination). In such cases, subjects may be re- evaluated during 
the screening period for  resolution of the illness to allow at least 
3 days of wellness before the planned vaccination as l ong as they 
remain within the 28 -day screening period.
 
 21. The subject has any significant disorder of coagulation (acquired 
or hereditary) requiring ongoing or intermittent treatment. Subjects 
receiving prophylactic antiplatelet medications, eg,  low-dose 
acetylsalicylic acid (≤100 mg/day or equivalent), and witho ut 
clinically apparent bleeding tendency, are eligible.  
22. The subject has a history of idiopathic urticaria. 
23. The subject has a documented history of alcohol abuse or drug 
addiction within 1 year before the planned day of dos e 
administration . 
24. The subject has a positive test result for drugs of abuse at 
Screening or on the day of first vaccination. 
25. The subject has any abnormality or permanent body art (eg,  tattoo) 
that, in the opinion of the investigator, would obstruct the ability 
to observe local reactions at  the injection site (deltoid region).  
26. The subject has any condition that, in the opinion of the 
investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or interpretation of study results (inclu
ding neurologic or psychiatric conditions 
deemed likely to impair the quality of safety reporting). 
27. The subject has a positive test result for hepatitis B surface antigen, 
hepatitis C virus antibody, or human immunodeficiency virus 
types  1 or 2 antibodies. 
28. The subject has donated blood or blood products >450 mL within 30 days of dosing.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 18 29. The subject has screening safety laboratory test results  (urine and 
serum) outside the normal range of the laboratory and with a 
toxicity score with  Grade  1 or higher. 
30. The subject has screening vital sign of blood pressure, heart rate, 
or respiratory rate that is equal to or greater than Grade  1 by 
toxicity score.  
31. The subject is an employee or first degree relative of the Sponsor, 
PPD, or study site personnel. 
Note that some  exclusi on criteria are time -related. A subject may be 
re-evaluated on more than one occasion during the screening period to 
assess for resolution. There is allowance to repeat an abnormal vital 
sign measurement and Grade 1 laboratory abnormalities (except  
aspartate aminotransferase, alanine aminotransferase, and alkaline 
phosphatase) once to allow for inclusion into the study and the last 
value measured will be used to allow inclusion in the study.  
 
Part  A Safety 
Assessments:  • Solicited AEs with toxicity scoring (local and systemic 
reactogenicity events) collected for 7 days following each 
vaccination  
• Unsolicited AEs collected for 28 days following each vaccination; additional classification if serious, medically attended, leading to study wi thdrawal, or an AESI  
• Safety laboratory test results with toxicity scoring ( hematology , 
serum chemistry , and coagulation) collected at 
Baseline and 
7 (+3 ) days  and 28 (+7) days following each vaccination 
• Urinalysis test results with toxicity scoring collected at Baseline and 7 (+3) days following each vaccination 
• A subset of  safety laboratory  test results ( as specified in Table  6-1) 
with toxicity scoring collected additionally at 17 (±3) days following each vaccination and 21 (+3)  days 
(sentinel subjects) 
following the first vaccination  
• Vital sign measurements with toxi city scoring on day of vaccination 
and 7 and 28 days following each vaccination 
Part  B Safety 
Assessments: • AESIs and SAEs through 1 year (or until resolved, whichever 
occur s first) following the last vaccination  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 19 Part  A 
Immunogenicity 
Testing:  • Neutralizing serum antibody titer s (PRNT50) to Zika (Baseline 
[pre-vaccination at Visit 1] and at 28 days following each 
vaccination [Visits  4 and 7, respectively])  
• Neutralizing serum antibody titers (PRNT50) to yellow fever 
(Baseline [pre- vaccination at Visit 1] and at 28 days following each 
vaccination [Visits  4 and 7, respectively])  in the 
flavivirus-seropositive group  
• T-cell response (cytokine activation  to IFN γ or other cytokines) 
(Baseline [ pre-vaccination at Visit 1] and at 7 days fo llowing each 
vaccination [Visits  2 and 5, respectively]) , if results of interim  
immunogenicity analyses  warrant further analyses of samples.  
Part  B 
Immunogenicity Testing:  • Neutr alizing serum antibody titer s (PRNT50) to Zika viru s at 
168 (±15) days and 364 (+ 15) days ( Visits  12 and 19, respectively)  
following the second vaccination will be evaluated if interim 
immunogenicity analyses  
warrants long term analyses of 
persistence.  
Study Drug, Dosage, and Route of Administration:  10-, 25- , or 100- µg mRNA -1325 or placebo (0.9% Sodium Chloride 
Injection, USP or BP) will be prepared as outlined in the pharmacy manual and administered via IM injection (0.5 mL) into the deltoid muscle on designated vaccination days. The second dose of study drug will be adminis tered preferably in the same arm used for the first dose.  
Sample Size:  Approximately 90 subjects are planned to be 
randomly assigned to 
receive study treatment . Formal sample size calculations were not 
performed. The number of subjects was chosen based on feasibility and is considered sufficient to meet the study objectives of identifying a dose and establishing initial safety results in a population of healthy adults in a non- endemic Zika region . 
Statistical 
Methods:  Safety:  Data from subjects who received  placebo will be pooled across 
cohorts for all treatments. Reactogenicity will be summarized by 
treatment assignment ( 10-, 25-, or 100-µg mRNA -1325 or placebo), 
vaccination (first or second), duration, and severity. Adverse events will 
be coded by preferred term and system organ class using the Medical Dictionary for Regulatory Activities and summarized by part, treatment 
assignment, vaccination (first or second), and overall. Adverse events will also be summarized by severity and relationship to the study 
vaccine. Descriptive statistics will be presented and the difference in the proportion of subjects with AEs will be provided comparing each dose 
level with placebo recipients across all groups. Individual subject 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 20 listings will be provided for all AEs, AEs leading to study withdrawal, 
AESIs, medically attended AE s, and SAEs.  
Safety data from clinical laboratory test results and vital sign 
measurements will be graded by severity scoring and analyzed by 
treatment group and vaccination (first or second). Absolute and change 
from baseline values will be provided according to the toxicity table, 
along with mean, median, and standard deviation. Results of serology, urine drug screen, and pregnancy test s will be listed for all subjects 
randomly assigned to receive study treatment . 
Medical history data for all subjects randomly assigned to receive study 
treatment  will be presented by subject in a listing.  
Baseline demographic and background variables will be summarized by treatment group and cohort for all subjects. The number of subjects who enroll in the study and the number and percentage of subjects who 
complete the study will be presented. Frequency and percentage of 
subjects who withdraw or discontinue from the study, and the reason for withdrawal or discontinuation, will also be summarized. 
Prior and concomitant medication will be listed (with start and stop 
dates) for each subject and summarized by common medical dictionary 
coding. Any vaccinations that occur during the trial conduct will also be captured and summarized.  
 
Immunogenicity : The following immunogenicity outc ome measures 
(for serum neutralizing antibody titer s) and their 95% CIs , where 
appropriate, will be summarized by treatment group and by visits after each vaccination:  
• Geometric mean titer  (GMT) of anti -
Zika virus neutralizing 
antibodies (PRNT50 assay) 
o Part A: A t Baseline ( pre-vaccination at Visit 1) and on 28 days 
after both first and second vaccination (Visits  4 and 7, 
respectively)  
o Part B: At 168 (±15) days and 364 ( +15) days (Visits  12 and 19, 
respectively)  will be evaluated if interim immunogenicity  
analyses  warrants long term analyses of persistence.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 21  • Geometric mean rati o (GMR) Post/Pre  
o Part A and Part B: The ratio of post- vaccination GMT to 
pre-vaccination ( Visit 1) GMT of subjects who have a baseline 
sample ( pre-vaccination at Visit 1) and post- vaccination sample 
at any post-dose time point ( Visits  4, 7, 12, or 19; data from 
visits 12 and 19 will be included only if based on interim 
immunogenicity analyses  results the evaluation of these later 
timepoints is warranted. ) 
• Seroconversion 
o Part A: The proportion of subjects with Zika virus PRNT50 titer 
≥1:10, ≥ 1:20, ≥ 1:40, ≥ 1:80, ≥ 1:160, and ≥ 1:320 at Baseline, 
Visit 4 , and Visit 7  
o Part A: The proportion of  subjects with baseline Zika virus 
PRNT50 titer <1:10 and post -vaccination  Zika virus PRNT50 
titer of ≥1:20; or with baseline Zika virus PRNT50 titer ≥1:10 
and with post- vaccination  4-fold titer  increase (Visits 4 or 7) 
o Part B: The proportion of subjects who maintained 
seroconversion status  at specific time points of 168  (±15) days 
and 364 (+15) days (Visits  12 and 19, respectively) . Data from 
visits 12 and 19 will be included only if based on interim immunogenicity analyses  results the evaluation of these later 
timepoints is warranted.  
• Cross -stimulation with prior flavivirus vaccination (subset of 
flavivirus- seropositive subjects ) 
o Part A: 
o Geometric mean titer  (GMT) of anti -yellow fever  neutralizing 
antibodies at B aseline, Visit 4 , and Visit 7  
o Geometric mean ratio  (Post/Pre) of anti -yellow fever 
neutralizing antibodies at  Visit 4 and Visit 7  
o The proportion of subjects with anti -yellow fever  antibody titer  
≥1:10, ≥ 1:20, ≥ 1:40, ≥ 1:80, ≥ 1:160, and ≥ 1:320 at B aseline, 
Visit 4 , and Visit 7  
o Additional neutralization assays for other flavivirus may be 
performed in select subsets  
 Following completion of each cohort in Part A, the database will be 
locked for that cohort and safety and immune test results will be 
analyzed through 28 days following the second vaccination. As dose 
escalation occurs, cumulative analyses will be included for each 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 22 subsequent data lock to allow for all prior dosing cohorts to be analyzed 
by cohort, treatment assignment, and in aggregate for mRNA -1325 
exposure. Immunogenicity and safety data, including mean group 
analyses of change from Baseline, where applicable, will be 
summar ized for each dos e cohort. These data are required to inform 
decisions on dose selection for this and other development programs 
using the same mRNA platform. Subject level treatment assignment will not be released to the subjects or to those individuals involved in managing or assessing safety in Part B of the study until that portion of the study is completed.  
Additional information can be found in the 
statistical analysis plan.  
Date of Protocol: 05 June 2017 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 23 List of Abbreviations  
 
Abbreviation Definition  
AE adverse event  
AESI  adverse event of special interest  
CBER  Center for Biologics Evaluation and Research  
CDC  Centers for Disease Control and Prevention 
CFR  Code of Federal Regulations  
DSPC  1,2 Distearoyl- sn-glycero -3-phosphocholine 
eCRF  electronic case report form  
ELISPOT  enzyme -linked ImmunoSpot  
EOS  end-of-study 
FDA  Food and Drug Administration 
GLP  Good Laboratory Practice 
GMR  geometric mean ratio  
GMT  geometric mean titer  
ICF informed consent form 
ICH International Council for Harmonisation  
IFNγ interferon gamma  
IM intramuscular  
IRB institutional review board  
IST internal safety team  
IV intravenous 
LLOQ  lower limit of quantification  
LNP  lipid nanoparticle 
MC3  DLin -MC3 -DMA  
MedDRA  Medical Dictionary for Regulatory Activities  
mRNA messenger RNA  
NOAEL  no-observed-adverse- effect level  
PBMC  peripheral blood mononuclear cell 
PRNT 50 P laque Reduction Neutralizing Titer EC50  
SAE  serious adverse event  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 24 Abbreviation  Definition  
SMC  Safety Monitoring Committee  
TEAE treatment -emergent adverse event  
ULOQ  upper limit of quantification  
VLP  virus -like particle  
WHO World Health Organization  
ZikaV  Zika virus 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 25 1 Introduction  
1.1 Background  
Zika virus ( ZikaV ) is a single -stranded  RNA flavivirus, which is transmitted to humans by a 
mosquito vector (mainly Aedes aegypti  but other Aedes  mosquitoes are believed to be 
competent vectors) or by person- to-person spread, mainly through sexual transmission. ZikaV  
has been found in blood and other body fluids (saliva, urine, semen) in which it can persist 
longer than in the blood ( Franca et al 2016 ). Due to the common vector, ZikaV  has a similar 
epidemio logy and transmission cycle to chikungunya and dengue.  Most infections are either 
asymptomatic or result in a mild febrile illness with a ras h. However, infection with ZikaV  is 
also causally associated with Guillain -Barré syndrome neuropathy and other neurological 
sequelae in infected adults as well as congenital malformation of  the brain (eg,  microcephaly, 
ventricular calcifications) and other  severe impairments (eg, intrauterine growth restriction) in 
infants born to mothers infected early in the pregnancy ( Brasil et al  2016).  
Currently there is no vaccine to protect against  this disease, which has spread rapidly from 
Asia to most tropical and  subtropical regions including the Americas. The Centers for Disease 
Control and Prevention (CDC) has listed Zika V as a Level  1 alert  (Brann 2016) . The World 
Health Organization (WHO) has declared ZikaV  to be a global public health emergency and 
has initia ted a strategic framework to aid in rapid response ( WHO, 2016a ). 
Moderna Therapeutics, Inc. has developed a proprietary messenger RNA ( mRNA)- based 
vaccine platform. This is based on the principle and observations that antigens can be produced 
in vivo by delivery and uptake of the corresponding mRNA by cells. The mRNA then 
undergoes intracellular ribosomal translation to endogenously express the protein antigen(s) encoded by the vaccine mRNA. This mRNA -based vaccine does not enter the cellular nucleus 
or interact with the genome, is non- replicating, and expression is transient. mRNA vaccines 
thereby offer a mechanism to stimulate endogenous production of structurally intact protein 
antigens in a way that mimics wild type viral infection  and is able to induce highly targeted 
immune responses against infectious pathogens such as ZikaV . 
mRNA-1325 is a n mRNA-based vaccine candidate being tested for its ability to safely induce 
an immune response with the intention to be able to prevent ZikaV  infection . 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 26 1.2 Non-clinical Studies in Development of mRNA -1325  
In support of development of mRNA-1325 for prophylaxis against ZikaV  infection, a number 
of non- clinical efficacy, distribution, and safety studies are being completed. These studies are 
summarized in Table  1-1. 
Table  1-1 Summary of Non-c linical Studies of mRNA -1325 
Name of Study  Duration  Species  Route of 
Administration  Formulation  
Efficacy  
An immunogenicity study to 
determine the ability of different doses of mRNA -1325 to induce 
IgG and neutralization titer s 
(PRNT50) against homologous and heterologous strains of Zika  42 days  Mouse  IM TRIS buffer 
pH 7.5 
Safety  
A 6-week, repeat -dose safety and 
immunogenicity study of mRNA -1325 in Sprague 
Dawley
® rat with 2 -week 
recovery  6 weeks 
(3 doses 
14 days 
apart) plus 
2-week 
recovery  Sprague 
Dawley rat  IM and ID  TRIS buffer, 
pH 7.5 
GLP 14 -day tissue distribution 
study of VAL506440 mRNA in CD-1 mice  14 days  CD-1 mice  IM TRIS buffer, 
pH 7.5 
Ames bacterial reverse mutation assay with MC3 and PEG2000- DMG Single 
exposure  E coli 
S typhymurium  In vitro  DMSO 
(PEG2000 -DMG)  
Ethanol (MC3)  
Mammalian cell micronucleus test in human PBLs with MC3 
and PEG2000- DMG  Single 
exposure  Human cells  In vitro  DMSO 
(PEG2000 -DMG)  
Ethanol (MC3)  
An in vivo mouse micronucleus study of VAL -506440 containing 
MC3 and PEG2000- DMG LNPs  Single dose  Mouse  IV 20 mM citrate buffer, pH 6.7  
Abbreviations: DMSO, dimethyl sulfoxide; GLP, Good Laboratory Practice; ID, intradermal; IgG, 
immunoglobulin G; IM, intramuscular; IV , intravenous; LNP, lipid nanoparticle; MC3, DLin -MC3 -DMA; 
mRNA, messenger RNA; PBL, peripheral blood lymphocyte; PEG2000-D MG, 1,2-Dimyristoyl -sn-glycerol, 
methoxypolyethyleneglycol ; PRNT50, Plaque Reduction Neutralizing Titer  EC50 . 
1.2.1 Non-clinical Pharmacology  
Based on clinical stage experiences with other flavivirus vaccines such as d engue 
(Dengvaxia™), the prME  polyprotein is expected to be processed by cellular proteases and 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 27 form secreted, non- infectious virus -like particles (VLPs). Using a Western Blot, Moderna 
Therapeutics, Inc. has demonstrated that transfection of mRNA -1325 in human HEK293 cells 
results in the expression of the encoded prME antigen. Negative stain electron microscopy of 
the supernatant of these cultures reveals large numbers of VLPs that are uniform in size at the expected diameter of approximately 40  nM. Other nucleic acid -based vaccines have also 
recently demonstrated the ability of the prME to protect non- human primates from ZikaV  
(Larocca et al 2016 ). 
1.2.2 Distribution  
A branched DNA hybridization assay was developed for the quantification of mRNA in the 
plasma and tissues. This assay has been used successfully for detection of mRNA from another 
closely related influenza mRNA vaccine (VAL -506440 encoding the HA antigen from the 
H10N8 influenza strain). This assay provides excellent sensitivity (5 -fg mRNA in 100- μg 
tissue) and specificity (200 t o 400 base fragment of the mRNA with multiple probes) with a 
reasonable dynamic range (3 -4 orders of magnitude). 
A study describing lipid nanoparticle (LNP) distribution in tissues after extravascular 
(intradermal and intramuscular [IM]) administration ind icated that the bulk of the dosed 
mRNA-1325 test article stayed near the site of administration (injection). It is highly 
improbable that a physiological mechanism exists that is capable of dramatic alteration of tissue distribution in closely related rode nt species (rat vs mouse). With this consideration, 
Moderna Therapeutics, Inc. believes that the data obtained for mice are relevant to rats as well.  
1.2.3 Toxicology  
Given that the mRNA -1325 product consists of both an RNA component and an LNP 
component, Moderna Therapeutics, Inc. has proposed completion of a comprehensive toxicology study of all key components. An IND -enabling repeat -dose IM toxicology study 
has been completed in male and female rats to examine the safety of t he full vaccine containing 
mRNA complexed with an LNP matrix . With regard to the safety of the novel excipi ent LNP 
components ( DLin -MC3 -DMA [ MC3 ] and PEG 2000- DMG), additional genetic toxicology 
studies consistent with International Council for Harmonisation  (ICH) S2 R1 have been 
completed and include in vitro and in vivo genetic toxicology assessments. In support of development of mRNA -1325, the in vivo component of this assessment was performed with a 
fully formulated, identical LNP -mRNA drug product containing a different mRNA sequence, 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 28 VA L -506440. The full results of these repeat -dose toxicity and genetic toxicology studies are 
provided in the investigator’s brochure. 
1.2.4 Genotoxicity  
mRNA-1325 is composed of not only mRNA, but also LNP components , cholesterol , 
1,2-Distearoyl -sn-glycero -3-phosphocholine (DSPC) , MC3, and PEG2000 -DMG. Cholesterol 
and DSPC represent commonly used lipid excipients in numerous approved parenteral 
products. In contrast, MC3 and PEG2000- DMG represent novel lipids not contained in any 
products currently approved by the Food and Drug Administration (FDA). MC3 is a custom -
manufactured, novel ionizable lipid that complexes with the active ingredient (mRNA) to form 
the LNP, while the 3 other commercial lipids (cholesterol, DSPC, and PEG2000- DMG) 
contribute to the overall pharmaceutical properties of the LNP. This type of lipid vehicle 
composition is currently in late -phase clinical studies conducted by Alnylam Pharmaceuticals 
to administer synthetic small interfering RNA via intravenous (IV)  infusion in patients 
suffering from transthyretin amyloidosis, and was shown to be well -tolerated in this population 
(Coelho et al 2013). Over 2  years of human clinical experience in Phase 2 studies have been 
reported as of 2015. 
In addition, both MC3 and PEG2000- DMG have also already been evaluated for safety and 
genotoxic potential in vitro and in vivo with the VAL -506440 H10N8 a vian influenza vaccine. 
Given that these are the same lipid components in the mRNA -1325 drug product, Moderna 
Therapeutics, Inc. contends that additional new genetic toxicity studies with mRNA -1325 or 
the same component lipids MC3 and PEG2000-DMG would not be informative. 
Moderna Therapeutics, Inc. has proposed completion of a Good Laboratory Practice (GLP) rat 
developmental and reproductive toxicology study, which will assess female Sprague Dawley rats only dosed at the highest anticipated clinical dose level and will include a control arm. 
Further details on all non -clinical research on mRNA -1325 can be found in the investigator’ s 
brochure. 
1.3 Clinical Studies with mRNA -1325  
No clinical studies with mRNA -1325 have been conducted to date. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 29 1.4 Rationale for Study  
No vaccines have yet been licensed for prophylaxis of ZikaV  infection . Of the approaches 
currently in development, the VLP and live attenuated vaccines ( Akahata et al 2010 ; Darwin 
et al 2011 ; Wang et al 2008; Brandler et al 2013 ) show the greatest pre -clinical potential. 
However, both are expected to be more complex, costly,  and longer to develop  and scale-up 
than mRNA due  to the need to establish, optimize , and characterize vaccine specific growth 
substrates, formulations , and dedicated production facilities. In addition, live attenuated 
vaccines, such as yellow fever vaccines , pose the risk of recombination with circulati ng wild 
type flaviviruses, reversion to pathogenicity , and vaccine -virus associated disease, particularly 
in immunocompromised populations. The Sponsor believes that on the basis of pre -clinical 
data with this and other vaccines in the Moderna Therapeutics , Inc. development pipeline, 
mRNA-1325 has the potential to achieve at least equivalent and more predictable levels of 
efficacy and safety , with more rapid  and reliably scalable manufacturing . 
The purpose of this Phase 1, first -in-human, randomized, placebo -controlled, dose -ranging , 
study is to evaluate the safety and immunogenicity of mRNA-1325 in healthy adult subjects  in 
a non- endemic region . The primary objective of this study is to assess the safety profile of 
mRNA-1325 compared with placebo. The  study will also evaluate immunogenicity by 
assessing changes from Baseline in ZikaV -specific neutralizing antibody titers. The safety 
profile and immune response(s) will be compared between flavi virus- seropositive and 
flavivirus- seronegative subjects to i ndicate the ability of the selected dose to safely protect 
populations in both endemic and non- endemic regions. 
1.5 Rationale for Dose Selection  
Dosing will begin with 10 µg (Cohort  2), followed by 25 µg (Cohort  3), and then 100 µg 
(Cohort 4). There will be no Cohort 1 included in this study. The 10 µg dose was chosen as a 
starting dose based on both pre -clinical data with mRNA -1325 and clinical data from two 
Phase 1 trials with different mRNAs in the same formulation as mRNA -1325. The pre -clinical 
no-observed-adverse- effect level (NOAEL) was established as 50 μ g for repeated IM dosing 
in the rat. This supports the starting dose of 10 µg in this study .  
In an ongoing clinical study with the Moderna mRNA H10N8 influenza vaccine, which utilizes  
the same the lipid composition as mRNA -1325, the tolerability profile of the vaccine 
administered according to a 2-dose vaccination  schedule in a dose range of 25 µg to 100 µg 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 30 was acceptable, and the vaccine induced a robust immune response. According  to Bahl  and 
colleagues ( Bahl et al 2017) , the majority of solicited AEs repor ted in the 100- µg group were 
mild (107/163 events; 66%) or moderate (52/163 events; 32%). The majority of events were 
injection site pain, myalgia, headache, fatigue, and chills/common- cold-like symptoms. Only 
4 events (2.5%), reported by 3 subjects, were categorized as severe and included injection site 
erythema ( 1.2% ), injection site induration ( 0.6%), and chills/common cold (0.6%). No related 
SAEs occurred in the study.  
In order to inform dose choices in this study, Moderna performed a group unblinding analysis 
of immunogenicity data from the first dose cohort (ie, Cohort 2: 10 µg of mRNA -1325). The 
analysis confirmed that the vaccine is able to induce neutralizing antibodies against Zika virus in both flavivirus -seronegative and flavivirus -seropositive subjects. Follo wing review of the 
immunogenicity results from this cohort and consider ing the variability of the serological assay 
and the biological variability of the immune response , Moderna decided to increase the dose 
for Cohort 4 from 50 µg  to 100 µg. 
Available non- clinical and  clinical data support the starting dose in this study of 10 μ g and a 
maximum dose of 100 μ g. 
1.6 Rationale for Study Design  
The study is designed to generate the safety and immunogenicity dat a required to select the 
optimal dose of mRNA-1325 for further development  in both endemic and non- endemic 
populations. Pre-clinical and clinical data support the expectation that a 2 -dose vaccination 
schedule, 1 month apart, will induce a protective immune response. This 2 -dose schedule will 
be explored at a  range of doses in 2 subpopulations: Non-endemic populations are represented 
by subjects recruited from the general population who are expected to be largely flavivirus seronegative.  This is confirmed through a baseline West Nile serology screening test, which if 
negative, excludes the most prevalent  flavivirus infection in the United States . Cross-reactivity 
of this test with other flaviviruses will establish a high certainty of baseline flavivirus na ïvety 
in this population. In addition, a proportion of subjects will be recruited who  have received a 
flavivirus vaccination  (yellow fever) within the preceding 20 years in order to assess the safety 
and immunogenicity profile in a homogeneous flavivirus -seropositive population in order to 
represent an endemic population.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 31 In order to explore vaccine tolerability , dosing will begin with 10 µg  (Cohort 2), and escalation 
to 25 µ g and 100 µg  will requir e review by the SMC of safety data collected from the preceding 
dose level cohorts. A dose-level cohort at 10 µg will be included to complete the dose ranging 
for safety and immunogenicity. For each cohort, a sentinel safety group will enroll 
3 flavivirus- seronegative subjects randomized to mRNA -1325 and followed for 7 days after 
first vaccination, with review of rea ctogenicity (Section 3.5.6) and safety laboratory results, 
prior to randomizing the remainder of the cohort. In addition, pause rules have been 
pre-established to trigger ad hoc SMC reviews , if required , and an internal safety team (IST) 
will review (blinded review) clinically significant safety laboratory test results, vital sign 
measurements, reactogenicity, and any AEs (all with toxicity scoring/grading) during the active vaccination phase of the trial.  
Immunogenicity will be assessed on the day of vaccination (before vaccination) and 
7 (+3) (cellular) and 28 (+ 7) (humoral) days following each vaccination. Longer- term safety 
and immune persistence  will be monitor ed for at least 1  year in a blinded follow -up period 
(Part  B). Immune persistence at 168 days and 364 days will be evaluated if interim 
immunogenicity analyses  warrants long term analyses of persistence. Data will be encoded 
into a safety database that wil l capture long -term safety across multiple Phase 1 (and possibly 
Phase 2) studies for this proprietary mRNA vaccine technology to allow safety to be monitored at the mRNA platform level.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 32 2 Study Objectives  
2.1 Primary Objective  
The primary objective of this stud y is to assess the safety of a 2 -dose vaccination schedule of 
mRNA- 1325 Zika vaccine, given 28 days apart, across a range of dose levels in 
flavivirus-seronegative and flavivirus-seropositive subjects compared with  placebo . 
2.2 Secondary Objective 
The secondary objective of this  study is to assess the immunogenicity of a range of doses of 
mRNA- 1325 Zika vaccine and to select a dose  for further development, based on changes 
from Baseline in the following tests : 
• ZikaV -specific neutralizing antibody titer s measured by a Plaque Reduction Neutralizing 
Titer EC50 (PRNT50); 
2.3 Exploratory Objective  
The exploratory objectives of this study are to : 
•  Assess the impact of mRNA -1325 Zika vaccine on a range of other functional and 
diagnostic flavivirus assays. 
• Assess ZikaV antigen -specific stimulation of T cells measured by interferon gamma 
(IFN γ) enzyme -linked ImmunoSpot (ELISPOT) on subject -derived peripheral blood 
mononuclear cells (PBMCs) , if results of interim immunogenicity analyses warrant 
further analyses of samples . 
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 33 3 Investigational Plan  
3.1 Study Design  
This is a Phase 1, double -blind, placebo- controlled, dose -finding study to evaluate the safety 
and immunogenicity of a range of dose levels of mRNA -1325 Zika vaccine given in a 2 -dose 
vaccination schedule, 28 days apart, and compared with  placebo in healthy adult subjects (18 
to 49 years of age, inclusive). mRNA -1325 is an mRNA -based vaccine candidate being tested 
for its ability to safely induce an immune response able to prevent ZikaV infection. 
ZikaV is a single -stranded  RNA flavivirus, which is transmitted to humans by a mosquito 
vector (mainly Aedes aegypti  but other Aedes  mosquitoes are believed to be competent vectors) 
or by person -to-person spread, mainly through sexual transmis sion. Currently there is no 
vaccine to protect against this disease, which has spread rapidly from Asia to most tropical and 
subtropical regions including the Americas. 
This is a 2 -part study. Part  A includes dose -finding, safety, and immune testing through 28 days 
following the second vaccination. Once subjects complete the final visit in Part  A, they will be 
entered into Part  B. Part  B is a blinded follow -up period with assessment of safety through 
12 months and immune persistence at 168 (±15) days and 364 (+15) days following the second 
vaccination in Part  A. Immune persistence at 168 days and 364 days will be evaluated if interim 
immunogenicity analyses  warrants long term analyses of persistence.  
 Part A  
Subjects will be randomly assigned in a blinded fashion in a n approximate 4:1 ratio to receive 
mRNA-1325 or placebo  at 1 of 3 dose levels ( 10 µg, 25 µg, or 100 µg), with each subject 
receiving 2  vaccinations separated by 28  (+7)  days. Dosing will begin with 10 µg (Cohort  2), 
followed by 25 µg (Cohort  3), and then 100 µg (Cohort  4). There will be no Cohort 1 included 
in this study. Approximately two -thirds of the enrolled subjects at each dose level will be 
flavivirus naïve and approximately one-third will be flavivirus seropositive as a result of 
having received a yellow fever vaccination in the past 20 years by either: a) military 
assignment in the previous 20 years that requires a yellow fever vaccination; or 2) yellow fever 
vaccination documented on an international certificate or other confirmatory do cumentation of 
yellow fever vaccination. 
Cohort and treatment assignment are shown in Figure 3-1. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 34 Figure 3-1 Cohort and Treatment Assignment  
Cohort  Flavivirus 
Status  Treatment Assignment  
(µg mRNA -1325 or placebo ) Total  
(Ratio)  
2 + 10 
30 
(4:1)  - 10 
+ placebo  
- placebo  
3 + 25 
30 
(4:1)  - 25 
+ placebo  
- placebo  
4 + 100 
30 
(4:1)  - 100 
+ placebo  
- placebo  
Abbreviations: +, flavivirus seropositive; -, flavivirus seronegative.  
For each cohort, a sentinel s afety group will occur with 3 flavivirus- seronegative subjects 
randomized to mRNA-1325 and followed for 7 days after first vaccination, with review of 
reactogenicity and safety laboratory results, prior to randomizing the remainder of the cohort. 
An IST will ove rsee the safety of the trial and will review blinded safety data during Part A of 
the study to ensure adherence to the protocol, monitor safety laboratory test results and 
reactogenicity, and raise concerns to the SMC should there be safety issues or operational challenges that could affect subject safety. Only after review by the IST of the blinded safety data (reactogenicity,  safety labs , and AEs) through 7 day s following first vaccination of the 
sentinel safety lead -in for each cohort planned will approval be given to allow randomization 
of the remainder of that cohort. The SMC will approve escalation to the next higher dosing cohort after review of blinded saf ety data of the currently dosed cohort through 7 days 
following the second vaccination and any cumulative safety data of all cohorts as the trial 
advances. The SMC will also be convened (ad hoc meeting) if a pause rule is triggered.  
A diagram of the dosing schema by cohort is shown in Figure 3 -2. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 35 Figure 3-2 Dosing Schema by Cohort 
 
Abbreviations: D, day; Plc, placebo; SMC, safety monitoring committee. 
Note: Yellow shading depicts safety follow -up of the first vaccination period and grey shading depicts safety 
follow -up of the second vaccination period for cohorts by dose sequence.  
Note: The SMC will approve escalation to the next higher dosing cohort after review of blinded safety data of the 
currently dosed cohort through 7 days following  the second vaccination and any cumulative safety data of 
all cohorts as the trial advances.  
 
The vaccine will be administered as an IM injection (0.5  mL) into the deltoid muscle as a 
2-dose vaccination schedule at Visits  1 and 4 (at least a 28 -day interval between dosing). The 
second dose of study drug will be administered preferably in the same arm used for the first 
dose. Vaccine accountability, dose preparation, and vaccine administration will be performed 
by unblinded pharmacy personnel, who will not participate in any other aspect of the study. The remainder of the site staff and all subjects will remain blinded to treatment assignment.  
Screening and consent will occur over a 28- day period before randomization (W est Nile virus 
serology screen can occur up to 90 days prior to randomization). A total of 30 subjects for each 
dose cohort will be assigned, 24 subjects to mRNA -1325 and 6 subjects to placebo 
(approximate 4:1 ratio overall). The first 3 subjects for each dose level will be randomized to 
mRNA-1325. Subjects who meet  all eligibility criteria  will receive the first vaccination at 
Visit 1. Of note, a subject who has met all eligibility criteria  but is noted to have a blood 
pressure, heart rate or respiratory rate that is Grade 2  or greater  (even after relaxing/resting) in 
the clinic on the day of vaccination should not receive a vaccination on that day and will need to return on a subsequent day for their vaccination. Similarly, if a subject has a fever (>37.9° C) 
or an inter current illness , vaccination should be withheld until resolved (as specified in 
exclusion criterion 20). Each subject will be monitored in the clinic for at least 1  hour following 
vaccination to assess for immediate reactogenicity, with vital sign measurements and local and 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 36 systemic reactogenicity toxicity scored at that time . The highest toxicity recordin g will be 
entered into the electronic case report form  (eCRF) . 
Subjects will be instructed on recording reactogenicity, AEs, and medications (prescription or 
over-the- counter) on the memory aid (ie, diary card), and will be provided measuring tools, 
and instructed to call or return to the clinic within 24 hours if a reactogenicity score reaches 
Grade 3 or greater during the first 7  days following vaccination. As standard practice, a 
reminder call will be made to the subject by the site a t least once during the first 7  days 
following each vaccination to answer any questions and ensure that the memory aid is being completed correctly  and consistently . All subjects will return on 7  (+3) (cellular PBMC testing) 
and 28 (+7) (humoral neutralization testing) days following each vaccination for safety assessments and blood sampling for immune testing. 
Safety assessments will include monitoring and recording of solicited (local and systemic 
reactogenicity) events (first 7 days after each vaccination); clinical laborat ory test results 
including hematology, serum chemistry, coagulation, and urinalysis; vital sign measurements; and physical examination findings ( Day 7 after each vaccination) and u nsolicited AEs 
(throughout Part  A). All unsolicited AEs and concomitant medication (including over the 
counter) usage will be collected. Specific categories of safety data collected will include SAEs, 
AEs of special interest (AESIs), AEs leading to study withdrawal, and medically attended AEs. 
At clinic visits, the investigato r will review, confirm, and grade the reactogenicity recorded in 
the memory aid and inquire about and review AEs and medications.  
All safety laboratory tests will be performed according to Table  6-1. Safety laboratory  tests 
will be performed during Screening (to allow for assessment of inclusion and exclusion criteria), on the day of first vaccination (Visit 1) , 7 (+3)  days following each vaccination  
(Visit 2 and Visit  5), and 28 ( +7) days following each vaccination (Visit 4 [prior to second 
vaccination] and Visit  7). At 17  (±3) days following each vaccination (Visit 3 and Visit 6) and 
at 21 [+3] days after the first vaccination (Visit 3a) for the sentinel subjects , a subset of safety 
laboratory tests will be performed as specified in Table  6-1. Blood test results (pre-vaccination) 
at Visit 1 wi ll be the basis for evaluation of changes from Baseline after vaccination.  
Blood samples for immunogenicity assessments (cellular and humoral) will be collected the day of vaccination (before vaccination) and 7 (+3) and 28 (+7) days , respectively,  followin g 
each vaccination. Subjects that miss the second vaccination due to noncompliance with the visit schedule and not due to a cohort pause will still be required to follow the original visit 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 37 and testing schedule. These subjects will be asked to undergo blood collection to comply with 
a second immune test at Visit 7 (56+7 days after first vaccination). 
To allow cohort advancement, the following data from the highest dosed cohort is expected to 
be reviewed by the SMC:  1) toxicity scoring of safety laboratory test results through 7 days 
following the second vaccination (through Visit 5); 2) toxicity scoring of vital signs and 
reactogenicity through 7 days following the first and second vaccination (through Visit 5); 
3) all unsolicited AEs (with grading and relatedness ). Data will be prepared  by dose category  
and timing relative to the last vaccination. As safety data on all cohorts accumulate, the SMC 
also review ongoing AEs as well as cumulative safety laboratory test results, reactogenicity, 
and AEs across vaccine doses for subjects remain ing in Part  A of the study, thereby providing 
a cumulative and comprehensive r eview of safety. Should a cohort pause occur due to 
pre-specified criteria, the SMC will be convened for an unscheduled (ad hoc) meeting and be 
provided with specific safety data related to the trigger of the pause.  
Part A is concluded for each subject at the time when they return to the clinic for Visit 7 
(28 days following the second vaccination). At that ti me, a subject will be entered into Part  B 
of the study. Once query resolution and immune testing is completed for each cohort in Part  A, 
the database will be locked. Results will be provided to the Sponsor, SMC, and IST. The Sponsor may determine whether dosing adjustments are required  during the conduct of the 
study based on either safety or immune responses per cohort. As dose escalation occurs, cumulative analyses will be included for each subsequent data lock to allow for all prior dosing 
cohorts to be  analyzed by cohort, treatment assignment, and in aggregate for mRNA -1325 
exposure. Subject -level  individual treatment assignment will not be released to the subjects or 
to those individuals involved in manag ing or assessing safety in Part  B of the study until that 
portion of the study is completed. 
The full schedule of events for Part  A is shown in Table  6-1. 
Part B – 12 Month Follow-u p After Final Vaccination  
To monitor for longer- term safety and immune persistence, each subject will be entered into a 
continued, blinded follow -up period (Part  B). This period will be conducted such that subjects, 
observers, and safety monitors will remain blinded to trea tment assignment. Part B of the study 
is initiated for a subject once they have returned for Visit 7 (28 days following the second 
vaccination). The safety database utilized for Part  B may be accessed by the pharmacovigilance 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 38 safety team for safety signal detection at scheduled intervals for ongoing assessments for a 
given vaccine candidate as well as for the mRNA platform technology.  
Once entered into Part  B, each safety contact will occur by telemedicine (eg, telephone, text  
message, internet) every 28 (±7) days, and blood samples for immune persistence will be 
collected from each subject at 168 (±15) days and 364 (+ 15) days following the second 
vaccination.  Immune persistence at 168 days and 364 days will be evaluated if  interim 
immunogenicity analys es warrants long term analyses of persistence.  Each safety contact will 
capture outcomes of any AESI or SAE that remains unresolved since the last visit or is newly 
identified through scripted query. The telemedicine visits may require a dditional data thr ough 
medically attended visits, in addition to and medications and vaccination taken by the subject 
during this time . Subjects will have consented during study enrollment to allow access to 
additional medical records needed to complete Part  B, thereby allo wing the blinding of the 
treatment assignment to be maintained.  
The full schedule of events for Part  B is shown in Table  6-2. 
When all subjects have completed their  final contact (approximately  12 months after their last 
vaccination), immune testing is completed, and all queries resolved, the database will be locked 
and analyzed with a final  clinical study  report provided to regulators. 
3.2 Selection of Study Population  
Healthy male or female subjects will be enrolled in at least 2  sites in the U nited S tates or its 
territories . Approximately 90 subjects  are planned to be  randomly assigned to receive study 
treatment . 
3.2.1 Inclusion Criteria 
Each subject must meet all of the following criteria during the screening period to be enrolled in this study:  
1. The subject is male or female between 18 and 4 9 years of age, inclusive. 
2. The subject has a body mass index between 18 and 35 kg/m
2, inclusive. 
3. The subject is considered by the investigator to be in good general health as determined by medical history.  
4. Female subjects must be non- pregnant and non- lactating and meet one of the following 
criteria: a) post- menopausal (defined as 12 consecutive months with no menses  without an 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 39 alternative medical cause or documented plasma follicle -stimulating hormone level in the 
post- menopausal range); b)  surgically sterile (ie, hysterectomy, bilateral tubal ligation, or 
bilateral oophorectomy). NOTE: these procedures and laborator y test results must be 
confirmed by physical examination or official written confirmation of a procedure ; c) if of 
childbearing potential  (defined as any female who has experienced menarche and who is 
NOT permanently sterile or post -menopausal) , agrees to be heterosexually inactive from 
at least 21  days prior to enrollment and through 3 months after the final vaccination or 
agrees to consistently use any of the following methods of contraception from at least 21 
days prior to enrollment and through 3 months after the final vaccination: condoms (male 
or female) with spermicide, diaphragm with spermicide, cervical cap with spermicide, intrauterine device, oral or patch contraceptives, Norplant
®, Depo -Provera®, or other 
FDA -approved contraceptive method that is  designed to protect against pregnancy. 
Periodic abstinence (eg, calendar, ovulation, symptothermal, post- ovulation methods) and 
withdrawal are not acceptable methods of contraception.  Male subjects must use an 
acceptable method of birth control (see above ) and must also agree to refrain from donation 
of sperm from the time of first vaccination until 3 months following the last vaccination. 
Periodic abstinence, declaration of abstinence for the duration of the study, and withdrawal 
are not acceptable method s of contraception. 
5. Subject assigned to the flavivirus -seropositive group has received a yellow fever 
vaccination in the past 2 0 years by either: a) military assignment in the previous 20 years 
that requires a yellow fever vaccination; or 2) yellow fever v accination documented on an 
international certificate or other confirmatory documentation. 
6. The subject understands and agrees to comply with the study procedures and provides written informed consent. 
7. The subject has access to a consistent and reliable means of telephone contact, which may be in the home, workplace, or by personal mobile electronic device. 
8. The subject agrees to stay in contact with the study site for the duration of the study, to provide updated contact information as necessary, and has no current plans to move from 
the study area for the duration of the study. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 40 3.2.2 Exclusion Criteria  
Subjects meeting any of the following criteria will be excluded from the study:  
1. The subject has any ongoing significant chronic illness requiring medical or surgical care. 
Asymptomatic conditions or findings (eg, mild hypertension, dyslipidemia) that are not associated with evidence of end -organ damage are not exclusionary provided that they are 
being appropriately managed and are clinically stable in the opinion of the investigator (ie, unlikely to result in symptomatic illness within the time -course of this study).  
2. The subject has a history of active cancer (malignancy) in the last 10 years (e xception is 
subjects with adequately treated non -melanomatous skin  carcinoma, who may participate 
in the study). 
3. The subject is a female of childbearing potential and has a positive pregnancy test at Screening or on the day of vaccination. 
4. The subject has abnormal liver enzyme tests ( increase in aspartate aminotransferas e, 
alanine aminotransferase, or alkaline phosphatase) at S creening.  
5. The subject has received another investigational product  in another investigational study 
within 60 days, or 5 half -lives, whichever is longer, before the planned date of first 
vaccination . 
6. The subject has received any live attenuated vaccines within 4 weeks before enrollment or inactive vaccines within 2 weeks before enrollment, or plans to receive any vaccine during the active vaccination period (through 4 weeks after their last planned vaccination). 
7. The subject has received (at any time) a vaccine for Zika or dengue vaccine.  
8. The subject has a history of confirmed Zika or dengue infection.  
9. The subject has lived in or visited any Zika -endemic area (as defined by WHO ; 
Appendix 4) greater th an 4 weeks in duration (flavivirus- seronegative group, only). 
10. The subject has received any  vaccination for a flavivirus (eg, yellow fever, Japanese 
encephalitis) in his or her lifetime (flavivirus -seronegative group, only) , or received a 
vaccination for a flavivirus more than 20 years ago (flavivirus- seropositive group, only). 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 41 11. The subject has a positive West Nile virus antibody titer above the detection level of the 
assay (flavivirus -seronegative group, only). NOTE: West Nile virus  titers are considered 
valid for a period of 90 days (allowing for the screening period on W est Nile virus to exceed 
the standard 28 days as noted for a ll other screening parameters ). 
12. The subject has reported previously participat ing in an investigational study involving 
LNPs . 
13. The subject has a history of hypersensitivity or serious reactions (eg, anaphylaxis, urticaria, 
other significant reaction) to previous vaccinations. 
14. The subject has any known or suspected autoimmune disease or immunosuppressive 
condition, acquired or conge nital, as determined by medical history and/or physical 
examination.  
15. The subject has a history of inflammatory arthritis.  
16. The subject has a neurologic disorder (eg, history of seizures, Guillain- Barré syndrome, 
dementia, vasculitis, or any known congenital or acquired disorder). 
17. The subject has a history of febrile disease with arthritis or arthralgia within 2 weeks of 
dose administration. 
18. The subject received immunoglobulins and/or any blood products within the 3 months preceding the administration of the study drug or plans to receive such products at any time during the study. 
19. The subject has had chronic administration (defined as more than 14 continuous days) of 
an im munosuppressant or other immune -modifying drug within 6 months before vaccine 
administra tion or plans to receive any products during the active vaccination period 
(through 4 weeks after their last planned vaccination). An immunosuppressant dose of a glucocorticoid will be de fined as a systemic dose of ≥10  mg of prednisone per day or 
equivalen t. The use of topical, inhaled, and nasal glucocorticoids will be permitted.  
20. The subject has any acute illness at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral body temperature >37.9°C on  
the planned day of vaccination). In such cases, subjects may be re -evaluated during the 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 42 screening period for resolution of the illness to allow at least 3  days of wellness before the 
planned vaccination as long as they remain within the 28- day screening p eriod . 
21. The subject has any significant disorder of coagulation (acquired or hereditary) requiring 
ongoing or intermittent treatment. Subjects receiving prophylactic antiplatelet medications, eg, low dose acetylsalicylic acid (≤100 mg/day or equivalent), and without clinically 
apparent bleeding tendency, are eligible.  
22. The subject has a history of idiopathic urticaria. 
23. The subject has a documented history of alcohol abuse or drug addiction within 1 year 
before the planned day of dose administration. 
24. The subje ct has a positive test result for drugs of abuse at Screening or on the day of first 
vaccination.  
25. The subject has any abnormality or permanent body art (eg, tattoo) that, in the opinion of 
the investigator, would obstruct the ability to observe local react ions at the injection site 
(deltoid region). 
26. The subject has any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or 
interpretation of study results  (including neurologic or psychiatric conditions deemed 
likely to impair the quality of safety reporting).  
27. The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus 
antibody, or human immunodeficiency virus types 1 or 2 antibodies. 
28. The subject has donated blood or blood products >450 mL within 30 days of dosing.  
29. The subject has screening safety laboratory  test results (urine and serum) outside the 
normal range of the laboratory and with a toxicity score with  Grade 1 or higher. 
30. The subject has screening vital sign of blood pressure, heart rate, or respiratory rate that is 
equal to or greater than Grade 1 by toxicity score. 
31. The subject is an employee or first degree relative of the Sponsor, PPD, or study site 
personnel. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 43 Note that some exclusion criteria are time -related. A subject may be re -evaluated on more than 
one occasion during the screening period to assess for resolution. There is allowance to repeat 
an abnormal vital sign measurement and Grade 1 laboratory abnormali ties (except aspartate 
aminotransferase, alanine aminotransferase, and alkaline phosphatase) once to allow for 
inclusion into the study and the last value measured will be used to allow inclusion in the study. 
3.2.3 Subject Restrictions During the Study  
3.2.3.1  General and Dietary  
To avoid false positive drugs of abuse S creening results,  subjects should refrain from  food or 
drink containing poppy seeds (eg, specialty breads and muffins) for 72 hours before the 
screening visit.  
3.2.3.2  Contraception and Pregnancy Avoidance Procedures  
Female subjects not  of childbearing potential must (defined as any female who has experienced 
menarche and who is NOT permanen tly sterile or post-menopausal) be post-menopausal 
(defined as amenorrhea for 12  consecutive months  without an alternative medical cause  or 
documented plasma follicle -stimulating hormone level in the post- menopausal range)  or 
surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). NOTE: 
these procedures and/or laborat ory test results  must be confirme d by physical examination or 
be provided through medical documentation. I f of childbearing potential, female subjects must 
be practicing a medically approved and highly effective method of contraception (defined as 
those which result in a low  failure rate [ie, less than 1%  per year] when used consistently and 
correctly).  
All female subjects of childbearing potential must have a negative pregnancy test at Screening 
and before dosing with study drug. Women of childbearing pote ntial must agree to be 
heterosexually inactive from at least 21  days prior to enrollment and through 3 months after 
the final vaccination or agree to consistently use any of the following methods of contraception from at least 21 days prior to enrollment a nd through 3 months after the final vaccination: 
condoms (male or female) with spermicide, diaphragm with spermicide, cervical cap with 
spermicide, intrauterine device, oral or patch contraceptives, Norplant
®, Depo- Provera®, or 
other FDA -approved contracep tive method that is designed to protect against pregnancy. 
Periodic abstinence (eg, calendar, ovulation, symptothermal, post- ovulation methods) and 
withdrawal are not acceptable methods of contraception. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 44 Male subjects must use an acceptable method of birth  control throughout the entire study (see 
above). Males must also agree to refrain from donation of sperm from the time of first 
vaccination until 3 months following the last vaccination. Periodic abstinence, declaration of abstinence for the duration of the study, and withdrawal are not acceptable methods of contraception. 
Female s ubjects of childbearing potential and male subjects will be provided with information 
on acceptable methods of contraception as part of the subject informed consent process and 
will be asked to sign a consent form stating that they understand the requirements for avoidance of pregnancy. 
3.3 Withdrawal of Subjects From the Study  
3.3.1 Reasons for Withdrawal  
Subjects can withdraw consent and discontinue from the study at any time, for any re ason, 
without prejudice to further treatment. 
The investigator can also withdraw a subject , upon the request of Moderna Therapeutics, Inc. 
or if Moderna Therapeutics, Inc. terminates the study. Upon occurrence of a serious or 
intolerable AE, the investigator will confer with the Sponsor or designee. If a subject desires 
to withdraw from the study because of an AE, the investigator will try to obtain agreement to continue to follow that subject for that event only until it is resolved or until stable  and the n 
complete an EOS form . In the event of a safety concern that results in with holding from further 
vaccination, the subject will be continued in the trial for safety evaluations.  
Every reasonable attempt will be made to follow subjects for safety  throughout the entire trial 
period even if further vaccination is withheld or the subject misses visits . The reason for subject 
withdrawal  or los t to follow -up will be documented. 
The investigator, in consultation with the Sponsor ’s medical monitor, may withhold a subject 
from further vaccination  if the subject experiences any of the following: 
1. Becomes pregnant;  
2. Develops, during the course of the study, symptoms or conditions listed in the exclusion 
criteria;  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 45 3. Experiences an AE (other than reactogenicity) after vacci nation that is considered by the 
investigator to be possibly or probably related to treatment and is of Grad e 3 (severe) or 
higher severity ; 
4. Experiences an AE or SAE that, in the judgment of the investigator, requires study drug 
withdrawal due to its natur e, severity, or required treatment, regardless of the causal 
relationship to treatment; 
5. Experiences a clinically significant change in clinical laboratory  test results, vital signs, or 
general condition that, in the judgment of the investigator, requires t reatment withdrawal; 
6. Experiences anaphylaxis clearly attributed to study vaccine;  
7. Experiences generalized urticaria related to the study vaccine.  
The reason for withdrawing or refusing from further vaccination will be recorded. In addition, 
if a subject re fused further vaccination they will be continued in the trial with all planned visits  
and assessments  relative to the vaccination schedule and including visits through 1 year post 
final vaccination.  
3.3.2 Handling of Withdrawals  
When a subject withdraws from the  study, the reason(s) for withdrawal will be recorded by the 
investigator on the relevant page of t he eCRF. These subjects will also be requested to complete 
all Visit 7 assessments. Any subject who fails to return for final assessments will be contacted 
by the site with a minimum of 3 phone call attempts, followed by a certified letter. After this 
final attempt the subject will be declared “lost to follow -up” on the EOS. 
Lost to follow -up is defined by the inability to reach the subject after a minimum of 
3 documented phone calls, faxes, text  messages, or emails as well as lack of response by 
subject to 1 registered mail letter. All attempts should be documented in the subject’s source documents.  
3.3.3 Replacements  
Any subject who is withdrawn, who is significantly outside the allowed vaccination window, or is lost to follow -up from the study will not be replaced  without the prior authorization of the 
Sponsor. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 46 3.4 Study Treatments  
3.4.1 Method of Assigning Subjects to Treatment Groups  
Subjects will be randomly assigned to a cohort after all entry criter ia have been satisfied on 
Visit 1. A randomization table will be pre -generated, and only the unblinded pharmacy 
personnel will have controlled access.  Subjects will be randomly assigned in a blinded fashion 
in an approximate 4:1 ratio to mRNA -1325 or placebo at 1 of 3 dose levels ( 10 µg, 25 µg, or 
100 µg). The first 3 subjects for each dose level will be randomized to mRNA -1325. 
Approximately t wo-thirds  of the enrolled subjects at each dose level will be flavivirus  naïve 
and approximately one-third  will be flavivirus seropositive as a result of having  received a 
yellow fever vaccination in the past 20 years.  
3.4.2 Treatments Administered  
Dosing will begin with 10- µg mRNA-1325 or placebo (Cohort  2), followed by 
25-µg mRNA- 1325 or placebo (Cohort  3), and then 100- µg mRNA-1325 or placebo 
(Cohort 4).  The rationale for dose selection is described in Section  1.5. Dosing c ohorts will 
advance as described in Section  3.4.2.1. 
Vaccine will be administered as an IM injection (0.5  mL) into the deltoid muscle as a 2 -dose 
vaccination schedule at Visits  1 and 4 (at least a 28 -day interval between dosing) . The second 
dose of study drug will be administered preferably in the same arm used for the first dose. 
The clinic will be appropriately staffed, trained on emergency resuscitation, and have stocked 
available rescue medications (such as epinephrine, steroids, antihistamines, and IV fluids) 
should any severe reaction (eg, anaphylaxis or profound urticaria) occur that requires 
immediate intervention.  
3.4.2.1  Dose Escalation  
Internal Safety Team  
An IST will oversee the safety of the trial and will review blinded safety data during Part  A of 
the study to ensure adherence to the protocol, monitor safety laboratory test results and 
reactogenicity,  and raise concerns to the SMC should there be safety issues or operational 
challenges that could affect subject safety. Pause rules have been pre -established to trigger ad 
hoc SMC reviews, if required ( Section  3.4.2.2), and the IST will review (blinded review) safety 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 47 laboratory test results, vital sign measurements, reactogenicity, and any AEs (all with toxicity 
scoring/grading) during the active vaccination phase of the trial. In addition, recruitment rates, 
timing of vaccination sequence , and window adherence will be reported to the IST. The 
chairperson of the IST may request that additional data be provided to the SMC that relates to 
the safety of subjects (eg, study conduct, quality issues, or safety concerns). 
At minimum, the IST will be composed of the Sponsor ’s study medical monitor  lead, the 
contract research organization’s medical monitor , and the principal investigator (s). The 
medical monitor  will oversee safety aspects of the study  and will participate as needed . 
Additional ad hoc mem bers may be included as needed.  
Safety Monitoring Committee 
The SMC will review data for dose escalation w hen at least 90% of subjects dosed (eg, ≥27 
out of 30 subjects) in Cohort  2 (10-µg mRNA -1325 or placebo) have safety data inclusive of 
their visit 7  days following the second vaccination ( Visit 5). Once a recommendation is given 
by the SMC, the Sponsor will approve advancing to Cohort  3 (25- µg mRNA -1325 or placebo). 
Cohort 4 ( 100-µg mRNA -1325 or placebo) will be randomized following SMC review and 
Sponsor approval of Cohort  3 (data inclusive of 7 days following the second vaccination of 
≥90% of subjects dosed [eg, ≥27 out of 30 subjects] ). 
To allow cohort advancement, the following data from the highest dosed cohort is expected to 
be reviewed by the SMC: 1)  toxicity scoring of safety laboratory test results through 7 days 
following the second vaccination (through Visit 5); 2) toxicity scoring of vital sign 
measurements  and reactogenicity th rough 7 days following the first and second vaccination 
(through Visit 5); 3) all unsolicited AEs (with grading and relatedness ). Data will be prepared  
by dose category  and timing relative to last vaccination. As safety data on all cohorts 
accumulate, the SMC will include in their review ongoing AEs as well as cumulative safety 
laboratory test results, reactogenicity, and AEs across vaccine doses as long as subjects remain 
in Part  A of the study, thereby providing a cumulative review of safety. Should a coh ort pause 
occur due to pre -specified criteria ( Section  3.4.2.2), the SMC will be convened for an 
unscheduled (ad hoc) meeting and receive specific s afety data related to the trigger of the pause.  
The SMC may recommend advancement to the next dosing cohort, request additional 
information prior to providing a recommendation, recommend stopping the study, recommend changes to study conduct and/or the protocol, or recommend additional operational 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 48 considerations due to safety issues that arise during study conduct. The Sponsor has the 
authority to accept (or amend) the SMC recommendations, to stop the study at any time, to 
request a cohort pause for safety concerns (to be addressed by the SMC), and to request 
additional consultation during study conduct for either safety concerns or operational issues. The SMC will also be convened should a pause rule be triggered or at the request of the IST, 
the investigator(s), or the Sponsor. 
The SMC will be comprised of 3 voting and independent members who are medical doctors 
familiar with Phase 1 clinical trial and safety review and independent from the trial. In addition, a biostatistician not associat ed with the trial will prepare the safety data  (non- voting member) , 
and a coordinator not associated with the trial will organize and record decisions of the SMC  
(non- voting member). The SMC may decide to include a non- medical person to weigh in on 
ethical  issues if the need arises.  
3.4.2.2  Pause Rules  
During the active vaccination period, if any of the following events occur and are assessed to be potentially mRNA-1325 related, the cohort will be paused for further enrollment and 
vaccination, and an unscheduled S MC will be convened to assess specific data concerns and 
make recommendations: 
• Two or more Grade 3 (or greater)  reactogenicity events (whether systemic or local) within 
a dose cohort following any single (eg,  the first, the second) vaccination  
• Two or more Grade 3 (or greater) same laboratory toxicity score within a dose cohort 
• One or more SAEs assessed as vaccine related, including any systemic hypersensitivity 
reaction  
An unscheduled SMC may also be convened (with vaccination pausing if deemed necessary), 
by the investigator, IST, or Sponsor, if any other significant safety or tolerability issues are identified in the comprehensive review of available data that warrant further evaluation before additional subjects are dosed. This may include emerging non- clinical data, clinically relevant 
AEs, or relevant data from other sources indicating safety concerns even if the event(s) per se does not meet the criteria specified in this section.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 49 Should a pause be triggered in the study, then each subject’s visits will  continue until the next 
scheduled vaccination visit. Should a pause affect a subject’s vaccination visit, then the 
window for that subject’s vaccination visit will be suspended until the pause is lifted and vaccination can resume. Once the pause is lifted  at the site, vaccination should be reinstated as 
soon as possible. Visits should thereafter be scheduled as if they had received their second 
vaccination within the 28 (+7) day time window. 
Should a pause be prolonged such that the second vaccination takes place outside the 
28 (+7)  day time window, the S ponsor has the option to add additional subjects in a dosing 
cohort to achieve the original number of subjects planned to be dosed within the 28 (+7)  day 
time window. If a subject is in the screening period for more than 28 days as the result of a 
pause, they may be rescreened for study eligibility as long as they continue to provide consent to participate in the study.  
Dosing adjustments may be made during the conduct of the study should the data reveal the  
need to adjust dosing due to the observed immune response or a change in the perceived 
benefit:risk ratio. However, treatment assignment will not be released to the subjects or to those individuals involved in managing or assessing safety in Part B of the  study until Part B of the 
study is completed.  
3.4.3 Identity of Investigational Product  
The mRNA-1325 I njection consists of the mRNA drug substance, mRNA-1325, which 
encodes the ZikaV  prME polypeptide, in an LNP formulation intended for IM injection.  
The mRNA-1325 LNP formulation includes 4 lipid excipients: MC3, an ionizable amino lipid 
(Jayaraman et al 2012 ), and the commercially available lipids cholesterol, DSPC, and 
PEG2000DMG ( Mui et al 2013), at a molar ratio of 50:38.5:10:1.5 for 
MC3:cholesterol:DSPC:PEG 2000- DMG. At pH below 6, the MC3 lipid is positively charged 
and binds to the negatively charged mRNA, thereby facilitating the formation of the mRNA/lipid complexes. Cholesterol is incorporated to provide structure and physicochemical stability to the par ticles. The neutral “helper” lipid, DSPC, is incorporated in order to increase 
the fusogenic properties of the particles. The polyethylene glycol lipid conjugate PEG2000-
DMG confers surface stabilization to the nanoparticles. The drug product formulation 
comprises 1.3 mg/mL m RNA-1325 drug substance and 26 mg/mL total lipid concentration.  
The placebo is 0.9% Sodium Chloride Injection, USP or BP.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 50 3.4.4 Management of Clinical Supplies  
3.4.4.1  Study Drug Packaging and Storage  
Moderna Therapeutics, Inc. will provide the investigator and study site with adequate 
quantities of mRNA-1325 Injection . The placebo (0.9% Sodium Chloride Injection, USP or 
BP) is commercially available and will be supplied by the  Sponsor or PPD . mRNA-1325 
Inject ion will be labeled “for clinical trial use ” and have all required labeling per regulations. 
mRNA-1325 Injection  will be supplied to the pharmacy in an unblinded manner. Each vial will 
be individually labeled for future subject identification purposes. 
mRN A-1325 I njection will be supplied in 2- mL glass vials with a 0.5 -mL fill volume. The 
unblinded study site pharmacy personnel will prepare a single dose (0.5 mL) for each subject 
based on the cohort and randomization assignment. A single vial may be used fo r multiple 
subjects  in a given day as long as the storage conditions are met and the vaccine is not refrozen. 
A pharmacy manual will be available and training provided to ensure pharmacy staff can 
comply with all vaccine storage, preparation, administration, and drug accountability procedures. 
mRNA-1325 Injection  must be stored in a secure area with limited access (unblinded pharmacy 
staff only), protected from moisture and light, and be stored at −20°C ± 5°C. The freezer  should 
have an automated temperature recording and alert system. There must be an available back -up 
freezer. The freezers must be connected to a  back -up generator. The pharmacy must have in 
place a 24 -hour alert system that allows for rapid response in case of freezer malfunctioning. 
In addition, drug accountability study personnel (eg, the unblinded pharmacy staff) are required 
to keep a temperature log to establish a record of compliance with these stor age conditions. 
The placebo will be stored according to the instructions on the product label and must also comply with storage in a restricted access area. Only drug accountability ( eg, unblinded 
pharmacy staff) should have access to the products used in this study.  
The site is responsible for report ing any mRNA -1325 Injection  that was not temperature 
controlled during shipment or during storage to the unblinded site (pharmacy) monitor. Such 
mRNA-1325 will be retained for inspection by the unblinded monitor and disposed of 
according to approved methods. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 51 3.4.4.2  Study Drug  Accountability 
It is the investigator’s responsibility that the unblinded pharmacy personnel maintain accurate 
records of receipt of all  mRNA-1325 Injection , including dates of receipt. In additi on, accurate 
records will be kept regarding when and how much mRNA-1325 is dispensed and used by 
each subject in the study. Reasons for departure from the expected dispensing regimen must 
also be recorded. To satisfy regulatory requirements regarding drug accountability, all 
mRNA-1325 Injection  will be reconciled and retained until study conclusion. At that time, 
mRNA-1325 Injection  will be destroyed or returned to the Sponsor according to applicable 
regulations. 
3.4.5 Blinding  
This is an observer -blind study. The investigator, study subjects, site monitors, and study site 
personnel will be blinded to the study drug administered, with the following exceptions: 
• Unblinded pharmacy personnel (of limited number) will be assigned to drug accountability 
procedures and  to prepare and administer mRNA -1325 (or placebo) to all subjects. The 
designee(s) will have no other study functions than study drug management, 
documentation, accountability, preparation, and administration. They will not be involved 
in subject evaluatio ns and will not reveal the study drug identity to either the subject or the 
study site personnel involved in the conduct of the study, unless this information is necessary in the case of an emergency.  
• An unblinded study monitor, not involved in other aspec ts of monitoring, will be assigned 
as the drug accountability monitor. They will have responsibilities to ensure the site is 
following all proper drug accountability, preparation, and administration procedures. 
• An unblinded statistician will provide a desc riptive analysis of safety and immunological 
endpoints after the completion of each dosing cohort. The interim analyses of 
immunogenicity data will be performed as outlined in Section  3.6.7. 
The treatment assignment will be concealed by having the unblinded designee(s) 
(eg, unblinded pharmacy staff) prepare the study drug in a secure location that is not accessible 
to other study personnel. The syringe used will maintain the blind at the time of vaccination 
(eg, a sleeve will be used should the vaccine substance be distinguishable in appearance 
between the mRNA-1325 and placebo). Only pharmacy staff will conduct the vaccination 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 52 procedure. Once the vaccination is completed, the blinded study staff will take over further 
assessments and interactions with the subjects. Access to the randomization code will be 
strictly controlled at the pharmacy.   
3.4.6 Breaking the Blind  
A subject or subjects may be unblinded in the event of an SAE or other event, or if there is a 
medical emergency requiring the identity of the drug to be known to properly treat a subject. 
If a subject becomes seriously ill or pregnant during the study, the blind will be broken only i f 
knowledge of the administered study drug will affect that subject’s treatment options. In the event of a medical emergency requiring identification of the study drug administered to an 
individual subject, the investigator will make every attempt to contact the medical monitor to 
explain the need  for opening the code within 24 hours of opening the code. The investigator 
will be responsible for documenting the time, date, reason for the code break, and the names 
of the personnel involved. 
In addition to the aforementioned situations where the blind may be broken, the data will also 
be unblinded to a statistical team at specified time points for interim analyses as outlined in Section  3.6.7. 
3.4.7 Treatment Compliance  
All doses of study drug will be administered at the study site under direct observation of study site personnel and appropri ately recorded (date and time) i n the eCRF. S ite personnel will 
confirm that the subject has received the entire dose of study drug. If a subject does not receive 
study drug or does not receive all of the planned doses, the reason for the missed dose will be 
recorded.  
Subjects that miss the second vaccination due to noncompliance with the visit schedule and not due to a cohort pause will still be required to follow the original visit and testing schedule. 
These subjects will be asked to undergo blood collection to comply with a second immune test 
at Visit 7 (56+7 days after first vaccination). 
The study site is responsible for ensuring subjects comply with the study windows allowed. 
Should a subject miss a visit, every effort will be made to contact the subject and achieve a 
visit within the defined v isit window. I f a subject exceeds their post- vaccination visit in excess 
of 28 days from the scheduled visit or misses a vaccination  schedule by more than 28 days (eg, 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 53 28 days beyond the scheduled time of vaccination) , then that visit will be classified as  a missed 
visit and the subject will continue with subsequent visits  for Parts  A and B of the study . All 
safety requirements of the missed visit will be captured and included in the follow -up visit (eg, 
safety laboratory testing, memory aid  review for reac togenicity , immune testing, as applicable).  
3.4.8 Prior and  Concomitant  Medications 
3.4.8.1  Prior Medications and Therapies  
Information about prior medications (including any prescription or over -the-counter 
medications, vaccines, or blood products) taken by the subject within the 30 days before 
providing informed consent (or as designated in the inclusion/exclusion requirement s) will be 
recorded in the subject’s eCRF.  
3.4.8.2  Concomitant Medications and Therapies  
In Part  A of the study, concomitant medications include all medications (including  vaccination 
outside of trial) taken by the subject from the time of signing the informed consent form (ICF) 
through 28 days after the second vaccination ( Visit  7) and will be recorded in the eCRF. In 
Part B, receipt of immunomodulators (including vaccines), immunosuppressants, or other 
concomitant medications that could potentially impact immune response will be collected through Visit 19. 
Subjects are prohibited from receiving immunoglobulins and/or any blood products within the 
3 months preceding the administration of the study drug or at any time during the study. Acetaminophen may be allowed a t the discretion of the investigator. A daily dose of ≤100 mg 
of aspirin given under the guidance of a physician is not a contraindication to enrollment. 
To allow accurate assessment of analgesic/antipyretic use during the 7 days after each 
vaccination, subjects will be inquired directly as to use (absent or present) and if used will be 
inquired for treatment or prophylaxis. 
Chronic administration (defined as more than 14 continuous days) of an immunosuppressant 
or other immune modifying drug within 6 months prior to vaccine administration or any such products during the active vaccination period (through 4 weeks after their last planned 
vaccination) is prohibited. An immunosuppressant dose of a glucocorticoid will be de fined as 
a systemic dose of ≥10  mg of prednisone per day or equivalent. The use of topical, inhaled, 
and nasal glucocorticoids will be permitted.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 54 Subjects are ineligible for the study if they have received (at any time) a vaccine for ZikaV  or 
dengue vaccine, any live attenuated vaccines within  4 weeks before enrollment, or inactive 
vaccines within 2 weeks before enrollment, or plan to receive any vaccine during the active 
vaccination period (through 4 weeks after their last planned vaccination). 
Concomitant medications (including vaccinations) will be coded using the WHO Drug 
Dictionary. If prohibited drug therapy is taken, a joint decision will be made by the investigator 
and the Sponsor to continue or withhold further vaccination of  the subject based on the time 
the medication was administered  and its pharmacology and pharmacokinetics, and whether the 
use of the medication will compromise the subject safety or interpretation of the data. It is the 
investigator’s responsibility to ensure that details regarding the concomitant medication are 
adequately recorded in the eCRF.  
3.5 Study Procedures  
Before performing any study procedures, all potential subjects will sign an ICF. The 
investigator must address all questions raised by the subject before the subject signs the ICF. 
The investigator will also sign the ICF. Subjects will undergo study procedures at the time points specified in the schedules of events ( Table  6-1 and  Table  6-2).  
At any time during the study a subject can be seen for an unscheduled visit. This may be prompted by abnormal laboratory test results, reactogenicity issues, or new or ongoing AEs. The site also has the discretion to make reminder phone calls or text  messages to inform the 
subject on visits, request further laboratory assessments, review memory aid content 
requirements, and follow up on ongoing or outstanding issues . As standard practice, a reminder 
call will be made to the subject by the site a t least once during the first 7 days following each 
vaccination to ensure that the memory aid is being completed correctly and consistently . 
Specific activities for each visit are outlined in Table  6-1 and Table  6-2 and may include the 
following: 
• Confirm subj ect identification  and conta ct information  
• Record vital sign s (toxicity scored) and p erform physical examination  
• Review memory aid   
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 55 • Grade reactogenicity  
• Assess for new AEs and follow -up on any outstanding AEs (including grading and 
relatedness ) 
• Review any new laboratory test results (toxicity scored ) and identify any laboratory tests 
that should be repeated 
• Record any concomitant medications and vaccinations since last visit 
• Collect blood samples as indicated by visit 
• Vaccinate (Visits 1 and 4 only) 
• Schedule follow-up appointm ents 
• Complete all eCRFs  
• Enroll subject in the continued blinded follow-up period ( Part B) (after subject has returned 
for Visit 7 [28 days following the second vaccination] in Part  A) 
3.5.1 Safety Contact  
Once entered into Part  B, each safety contact will occur by telemedicine (eg, telephone, text  
message, internet), and blood samples for immune persistence will be collected from each 
subject at the time points indicated in Table  6-2. 
Safety contacts must be performed by appropriately trained study site staff. If the initial contact 
is unsuccessful, the study site staff should make a total of 3 attempts for each scheduled safety 
contact. All attempts to contact the subjects will be recorded in the source documents. The 
safety contact is considered missed if there is a failure to contact the subject by the time of the 
succeeding visit (every 28  days  plus window allowance ).  
These contacts will follow a script, which will facilitate the collection of relevant safety 
information. Each safety contact will capture outcomes of any  AESI or SAE that remains 
unresolved since the last visit or is newly identified through scripted query. Additional data 
may be requested thr ough medically attended visits, and medications and vaccination will be 
recorded as part of the medical intake for each telemedicine visit. All safety information 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 56 described by the subject must be documented in the source documents and not documented on 
the script used for the safety contact.  
3.5.2 Completion of Memory Aid  
The memory aid utilized will be a  diary card (paper ) and is a method to record systematic 
collection of AE information from the subject; this information is subject to potential change based on further questioning and/or follow -up by study staff. Each subject will be instructed 
to complete a memory aid  to describe: 
• Solicited local and systemic AEs ( Section 3.5.6) occurring ( with appropriate 
documentation to allow severity  scoring by the investigator ) during the day of each dose 
administration and for the following 7 days  
o Daily oral body temperature measurement is to be performed at approximately the same 
time each day using the thermometer provided by the study site. If  body temperature is 
taken more than once in a given day, only the highest temperature reading will be 
recorded.  
o For solicited local AEs that require measurement, the measurement of size will be 
performed using the ruler provided by the study site. 
• All medications (excluding vitamins and minerals) taken durin g the day of each vaccine 
administration and for the following 28 days  
• Any unsolicited AE during the first 28 days following each vaccination  
Study staff will review the information regarding solicited and unsolicited AEs, body temperature, and concomitant  medications  during the clinic visit . This information will be 
recorded in the subject’s source documents and the eCRF. 
3.5.3 Immunogenicity  Assessments  
Blood samples for immunogenicity (cellular and humoral) assessment s will be collected at the 
time points indicated ( Table  6-1 and Table  6-2). Sample aliquots will be designed so as to 
ensure that back up samples are available and adequate vial volumes will allow for testing 
needs. The actual time and date of each sample collected will be recorded in the eCRF and 
unique sample identification will be utilized to maintain the blind at the laboratory at all times 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 57 and to allow for automated sample tracking and housing. Handling and preparation of the 
samples for analysis, as well as shipping and storage requirements will  be provided in a 
separate laboratory manual.  
Immunogenicity endpoints are provided in Section  3.6.2. 
3.5.4 Total Blood Volume  
The approximate blood volumes to be collected from each subject during the study are 
provided in Table  3-1. 
Table  3-1 Total Blood Volume  
Assessment  Blood Volume per 
Sample  Scheduled Number of 
Collectionsa Total Amount of 
Scheduled 
Blood  
Clinical Laboratory Assessments  
Hematology 2 mL 6 12 mL 
Serum chemistry  6.5 mL 9 58.5 mL 
Coagulation  3 mL  9 27 mL 
West Nile virus  2.5 mL 1 2.5 mL 
Serologyb 6 mL 1 6 mL 
Immunogenicity Assessments  
ZikaV -specific neutralizing antibody 
titers measured by PRNT50c  10 mL 5 50 mL 
ZikaV  antigen -specific stimulation of 
T cells measured by IFNγ ELISPOT 
on subject -derived PBMCs  40 mL 3 120 mL 
ZikaV exploratory testingc 10 mL  5 50 mL 
Subject T otal 326 mL 
Abbreviation s: ELISPOT, enzyme -linked ImmunoSpot;  HIV , human immunodeficiency virus; IFN γ, interferon 
gamma; PBMC,  peripheral blood mononuclear cell; PRNT50, Plaque Reduction Neutralizing Titer EC50; YF, 
yellow fever; ZikaV , Zika virus . 
a Additional blood collections may be required at the discretion of the investigator to follow up on abnormal 
results.  
b Serology testing will include hepatitis B surface antigen, hepatitis C virus antibody, and HIV virus type  1 
and 2 antibodies.  A separate counseling and consenting for HIV testing will occur.  
c For the PRNT50 and ZikaV exploratory testing, 3 samples will be collected during Part A of the study ( Visits 
1, 4, and 7), and 2 samples will be collected during Part B of the study (Visits 12 and 19).  
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 58 3.5.5 Safety Assessments 
Safety assessments will include monitoring and recording of solicited (local and  systemic 
reactogenicity events ) and unsolicited AEs ; SAEs, AESIs, AEs leading to study withdrawal, 
medically attended AEs, clinical laboratory test results including hematology, serum chemistry, 
coagulation, and urinalysis; vital sign measurements; and physical examination findings . 
3.5.6 Solicited Safety Measurements  
The term “reactogenicity” refers to selected signs and symptoms (AEs) occurring after dose 
administration, to be collected by the subject during the day of each dose administration and 
for the following 7 days using self -reporting and the memory aid . Subjects will be instructed 
to call or return to the clinic within 24  hours if a reactogenicity score reaches Grade 3 or greater 
during the first 7 days following vaccination.  
The following AEs are included in the memory aid : 
Solicited local AEs include:  
• injection site induration/swelling  
• injection site tenderness  
• injection site erythema/redness 
• injection site pain  
Solicited systemic  AEs include: 
• body temperature  (oral)  
• generalized myalgia (muscle ache or pain)  
• generalized arthralgia (joint ache or pain)  
• headache  
• fatigue/malaise  (unusual tiredness) 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 59 • nausea/vomiting  
• diarrhea  
The solicited AEs will be recorded daily by subjects using the memory aid; where appropriate 
reactogenicity measurements will be taken using the tools provided (oral thermometer and 
measuring device). The investigator will later review, confirm, and grade reactogenicity, 
according to  the Guidance for Industry: Toxicity  Grading Scale for Healthy Adult and 
Adolescent V olunteers Enrolled in Preventative Vaccine Clinical Trials ( Center for Biologics 
Evaluation and Research [ CBER ] 2007; Table  6-3). If a solicited local or systemic AE 
continues beyond 7 days after dose administration, it will also be recorded as an AE in the 
eCRF from 8 days after vaccination until resolved or stable. 
Other solicited reactions: 
Use of anal gesics  and/or antipyretics will be recorded as absent or present, and it will be 
indicated if they were used for treatment or for prophylaxis. 
Solicited local and systemic AEs (including body temperature) will be collected using the 
memory aid  during the day of each dose administration and for the following 7 days. To 
improve recall for the next visit, subjects will record incidence of unsolicited AEs and any 
medication (prescription and over the counter) using the memory aid for 28 days after each 
vaccine administration.  
All AEs necessitating an un scheduled physician visit, medical attention, or leading to 
withdrawal from the study will also be collected throughout Part  A of the study, and all AEs 
will be monitored until resolution or, if the AE becomes chronic, a cause is identified. If an AE 
is unresolved at the conclusion of Part  A of the study, a clinical assessment will be made by 
the investigator and the medical monitor to determine whether or not continued follow -up of 
the AE is warranted . The relationship of the study drug to any AE and any SAE will be 
determined by the investigator as related  or not related. All AEs resulting in withdrawal of the 
subjects from the study will be documented in the source documents and in the eCRF. 
For Part  B of the study, a script will be utilize d to query for any new SAE s or AESI s, and 
proper documentation will be obtained to allow an assessment of relatedness to vaccination or 
study participation. All SAEs and AESIs will be followed to resolution, to chronic stable state, 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 60 or until the last subject visit for Part B occurs. At that time , any ongoing AEs will receive their 
final classification so that the safety database can be locked.  
A tabulation of all SAEs and AESIs , categorized by  the Medical Dictionary for Regulatory 
Activities (MedDRA) preferred terms and assessed relationship to study drug , will be 
performed.  
3.5.7 Unsolicited Safety Measurements  
3.5.7.1  Adverse Events  
The investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug or their clinical significance. If there is any 
doubt as to whether a clinical observation is an AE, the event should be reported.  
3.5.7.1.1  Definitions 
An AE is defined as any untoward medical occurrence associ ated with the use of a drug in 
humans, whether or not considered drug related. Subjects will be instructed to record any AEs (solicited or unsolicited)  in the memory aid . 
A treatment -emergent AE (TEAE) is defined as any event not present before exposure to study 
drug or any event already present that worsens in intensity or frequency after exposure. 
A suspected adverse reaction  is any AE for which there is a reasonable possibility that the study 
drug caused the AE. For the purposes of investigational new dr ug safety reporting, “reasonable 
possibility”  means that there is evidence to suggest a causal relationship between the study 
drug and the AE. A suspected adverse reaction implies a lesser degree of certainty about 
causality than adverse reaction, which means any AE caused by a study drug. An adverse 
reaction is any AE caused by a drug. Adverse reactions are a subset of all suspected adverse 
reactions for which there are reasons to conclude that the drug caused the event.  
An AE or suspected adverse reaction  is considered “unexpected” if it is not listed in the 
investigator ’s brochure or at the specificity or severity that has been observed with the study 
drug being tested; or, if an investigator ’s brochure is not required or available, is not consistent 
with the risk information described in the general investigational plan or elsewhere in the 
current application. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator ’s brochure referred only to elevated hepatic 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 61 enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be 
unexpected (by virtue of greater specificity) if the investigator ’s brochure listed only cerebral 
vascular accidents. “Unexpected,” as used in  this definition, also refers to AEs or suspected 
adverse reactions that are mentioned in the investigator ’s brochure as occurring with a class of 
drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. 
Unsolicited AEs  will also be evaluated by the investigator for the coexistence of any of the 
other following conditions: 
• Medically  attended AE: an AE that leads to an unscheduled vis it to a healthca re practitioner  
Any solicited AE that meets any of the following criteria must be entered as an AE  in the AE 
page in the database: • Laboratory test or vital sign measurements with a toxicity score of Grade 3 or greater  
• Solicited local or systemic AE leading  to the subject withdrawing from the study or the 
subject being withdrawn from the study by the investigator  
• Solicited local or systemic AE lasting beyond 7 days post- vaccination  
• Solicited local or systemic AE that lead to subject withdrawal from study drug 
• Solicited local or systemic AE that otherwise meets the definition of an SAE  
3.5.7.1.2  Serious  Adverse Events  
An AE or suspected adverse reaction is considered “serious” (SAE) if, in the view of either the 
investigator or Sponsor , it results in any of the follo wing outcomes: 
• Death  
• Life-threatening AE  
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 62 • Congenital anomaly or birth defect 
• Other medically important event 
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the subject and may require  medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
An AE or suspected adverse reaction is considered “life threatening” if, in the view of either 
the investigator or Sponsor , its occurrence places the subject at immediate risk of death. It does 
not include an AE or suspected adverse reaction that, had it occurred in a more severe form, 
might have caused death.  The investiga tor must immediately (within 24  hours of awareness) 
report to the Sponsor any SAE through the agreed upon reporting mechanism. 
3.5.7.1.3  Adverse Events of Special Interest  
Certain AESIs are evaluated after the administration of immunostimulatory agents. All subjects enrolled in the study will be monitored for AESIs from enrollment through the end -of-study 
(EOS ) visit. The occurrence of any of these AEs will be treated as an SAE, meeting the criterion 
of a “medically important event.”  
The list of AESIs is presented in Section  6.2. 
A diagnosis of an AESI will be reported to the Sponsor in an expedited manner similar to  an 
SAE. The AESI diagnosis, as well as any medications taken to treat the condition, will be recorded  in the subject’s eCRF.  
3.5.7.1.4  Pregnancy  
The investigator is required to inform the Sponsor about any unexpected case of pregnancy 
occurring during the study (for female subjects), monitor the pregnancy until delivery, and 
report whatever outcome to the Sponsor ( no later than 1 week after becoming aware of the 
pregnancy). 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 63 Pregnancy report forms will be distributed to the study site to be used for this purpose. 
The investigator must immediately (within 24 hours of awareness) report to the Sponsor any 
case of pregnancy resulting in an abnormal outcome (miscarriage or newborn with congenital abnormality and/or stillbirth) according to the procedures described for SAEs. 
3.5.7.2  Eliciting and Documenting Adverse Events  
The investigator is responsible for ensuring that all AEs and SAEs are recorded in the eCRF and reported to Moderna Therapeutics, Inc. In Part  A of the study, AEs  will be assessed from 
the time of the first dose administration at Visit 1 through Visit 7. However, for the time period 
after the ICF is signed until before receiving the study drug, AEs will only be recorded when 
they are defined as one or more of the following: SAEs, AESIs, or AEs leading to study 
withdrawal . In Part  B of the study, AESIs and SAEs  will be assessed from Visit 8 through 
Visit 19. Any AEs occurring before receipt of the study drug will be analyzed separately from 
TEAEs.  
At every clinic visit or telephone contact, subjects will be asked a standard question to elicit 
any medically  related changes in their well -being according to the scripts provided. Subjects  
will also be asked if they have been hospitalized, had any accidents, used any new medications, or changed concomitant medication regimens (both prescription and over -the-counter 
medications).  
In addition to subject observations, data from clinical laboratory test results , physical 
examination findings , or other documents relevant to subject safety classified as an AE will be 
documented on the AE page of the eCRF. 
3.5.7.3  Reporting Adv erse Events  
All unsolicited AEs reported or observed during the study will be recorded on the AE page of 
the eCRF. Information to be collected includes drug treatment  and dose, type of event, time of 
onset, investigator -specified assessment of severity and  relationship to study drug, time of 
resolution of the event, seriousness, as well as any required treatment or evaluations, and 
outcome. The unsolicited  AEs resulting from concurrent illnesses, reactions to concurrent 
illnesses, reactions to concurrent medications, or progression of disease states must also be reported. All AEs will be followed until they are resolved or stable or judged by the investigator to be not clinically significant. The MedDRA will be used to code all unsolicited  AEs.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 64 Any medical  condition that is present at the time that the subject is screened but does not 
deteriorate should not be reported as an unsolicited  AE. However, if it deteriorates at any time 
during the study, it should be recorded as an unsolicited AE. 
Any AE considere d serious by the investigator or which meets SAE criteria ( Section  3.5.7.1.2) 
must be reported to the Sponsor immediately (within 24 hours of becoming aware of the SAE). 
The investigator will assess whether there is a reasonable possibility that the study drug caused 
the SAE. The Sponsor will be responsible for notifying the relevant regulatory authorities of any SAE as outlined in the 21 US Code of Federal Regulations (CFR) Parts 312 and 320. The investigator is responsible for notifying the institutional review board ( IRB) directly.  
The following contact information is to be used for SAE reporting: 
SAE Hotline:  
SAE Fax line:  
3.5.7.4  Assessment of Severity  of Unsolicited Adverse Events  
The severity (or intensity) of an AE refers to the extent to which it affects the subject’s daily 
activities and will be classified as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or potentially life threatening (Grade 4) using the following criteria:  
• Mild (Grade 1): These events do not interfere with the subject’s daily activities.  
• Moderate (Grade 2): These events cause some interference with the subject’s daily 
activities but do not require medical intervention. 
• Severe (Grade 3): These events prevent the subject’s daily activity and require medical 
intervention. 
• Life threatening (Grade 4): These events require an emergency room visit or hospitalization.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. An AE characterized as intermittent 
requires documentation of onset and duration of each episode. 
The Toxicity Grading Scale for Healthy Adult and Adolescent V olun teers Enrolled in 
Preventative Vaccine Clinical Trials ( CBER 2007) will be used to categorize solicited 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
PPD
PPD
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 65 reactogenicity, safety laboratory test results, and vital sign measurements observed during this 
study. Specific criteria for clinical and laboratory abnormalities are presented in Table  6-3 and 
Table  6-4, respectively, and will be graded if outside of the reference range for  the laboratory 
utilized. Of note, the laboratory test value itself may not be the AE classification. Each AE will 
be classified by its most specific term (eg, renal insufficiency, bronchitis) and supporting 
evidence (eg, laboratory test value, x- ray) will  not be classified as an AE per se.  
3.5.7.5  Assessment of Causality  
The investigator’s assessment of an AE’s relationship to study drug is part of the 
documentation process but is not a factor in determining what is or is not reported in the study.  
The investigator will assess causality (ie, whether there is a reasonable possibility that the study drug caused the event) for all AEs and SAEs. The relationship will be characterized using the following classification: 
• Not related: There is not a reasonable possibility  of Sponsor's product relationship: Subject 
did not receive the S ponsor’s product OR temporal sequence of the AE onset relative to 
administration of the Sponsor’s product is not reasonable OR the AE is more likely 
explained by another cause than the Sponsor’s product.  
• Related: There is a reasonable possibility of S ponsor’s product relationship: There is 
evidence of exposure to the S ponsor’s product. The temporal sequence of the AE onset 
relative to the administration of the S ponsor’s product is reasonable.  The AE is more likely 
explained by the Sponsor’s product than by another cause. 
3.5.7.6  Follow -up of Adverse Events  
All AEs must be reported in detail on the appropriate page of the eCRF and followed until the 
AE is resolved or stable or judged by the investigator to be not clinically significant in Part A of the study. For Part B of the study, only  AESIs and SAEs will be recorded. The investigator 
may request an unscheduled visit at any time , if warranted.  
3.5.8 Clinical Laboratory Testing  
Clinical laboratory tests will be performed by the central  laboratory , unless specified otherwise . 
Blood and urine will be collected in Part  A at the time points indicated in the schedule of events 
(Table  6-1). Fasting is not required before collection of laboratory samples. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 66 The following hematology, serum chemistry, urinalysis , and other laboratory  assessments will 
be performed . The results will be toxicity scored using Table  6-4. 
Hematology:  Hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration, mean corpuscular volume, platelet count, red 
blood cell count, and total and differential white blood cell count 
Serum 
chemistry:  Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, 
amylase, lipase, bilirubin (total and direct ), blood urea nitrogen, creatinine, 
random glucose, potassium, sodium, total protein, albumin, and calcium 
Females subjects only: β-human chorionic gonadotropin ( childbearing 
potential) and follicle -stimulating hormone (post-menopausal) 
Urinalysis:  pH, protein, glucose, ketone, bilirubin, urobilinogen, blood, nitrite, 
leucocytes, and specific gravity  
Coagulation : Prothrombin time and partial thromboplastin time  
A pregnancy test ( β-human chorionic gonadotropin) will be performed on all female subjects 
of childbearing  potential at Screening  (serum pregnancy test), before each dose administration 
(urine pregnancy test ), and as needed at unscheduled visits (serum pr egnancy test) . Serum 
pregnancy tests will be sent to the central laboratory, while urine pregnancy tests will be 
performed by the local laboratory on site . A follicle -stimulating hormone test will be performed 
at Screening, as necessary, to confirm post- menopausal status in female subjects, if not 
documented in the subject’s medical records . 
Human immunodeficiency virus (types 1 or 2) antibody, hepatitis B surface antigen, and 
hepatitis  C virus antibody will be assessed at Screening. 
At Screening, if the subject has no proof of y ellow fever vaccination within 20 years, or other 
documentation of flavivirus status, the West Nile virus screening test will be administered.  A 
West N ile virus ser ology screen can occur up to 90 days prior to randomization. 
A urin e screen for drugs of abuse will be performed by the local laboratory at Screening and 
before dose administration at  Visit 1 for opiates, cocaine,  phencyclidine, amphetamines, 
benzodiazepines, and methadone (cannabis excluded). 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 67 Should safety laboratory testing at 7 days post -vaccination result in a Grade 2 or greater 
toxicity score, then repeat testing within the next 10 days must occur and this may include an 
unscheduled visit. Should the subject’s laboratory test value not return to Baseline then 
periodic testing may be needed until the abnormality is deemed to be associated with a new 
stable AE or determined to be not clinically significant by the investigator.  
Those values that fall within the normal range of the laboratory will automatically be classif ied 
as normal and receive a toxicity score of 0. All values that have a toxicity score of Grade 1 or 
greater will also be evaluated by the investigator and classified as “abnormal clinically 
significant (CS)”, or “abnormal not clinically significant (NCS). ” Investigators should use their 
clinical judgment when considering the clinical significance of any abnormal laboratory findings. All laboratory test values with a toxicity score of Grade 3 or greater will be entered 
as AEs. Any additional laboratory test value that is determined to be clinically significant will 
also be recorded as an AE , should that be considered the primary diagnosis. In such instances, 
the abnormal value and grade will be documented on the AE page of the eCRF. The investigator 
will continue to monitor the subject with additional assessments until the values have reached the reference range or the values at Screening or until the inve stigator determines that follow -
up is no longer medically necessary. The only exception to this rule would be a laboratory test 
value that is associated with an identified ongoing AE where that event would be the classifying AE. 
3.5.9 Vital Sign Measurements 
Vital sign measurements will include systolic and diastolic blood pressures, heart rate, respiratory rat e, and body temperature  (which is classified as a solicited systemic event) . The 
subjec t will be seated for at least 5  minutes before all measurements are taken. Vital signs will 
be measured in Part  A at the time points indicated in the schedule of events ( Table  6-1). 
When procedures overlap and are scheduled to occur  at the same time point, the order of 
procedures should be vital sign measurements and then the blood collection. 
If any of the vital sign measurements meet the toxicity grading criteria for clinical 
abnormalities ( Table  6-3) of Grade  3 or higher, the abnormal value and grade will be 
documented on the AE page of the eCRF  (unless there is another known cause of the 
abnormality and that would result in an AE classi fication) . The investigator will continue to 
monitor the subject with additional assessments until the value has reached the reference range, 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 68 the value at Screening , is considered stable, or until the inve stigator determines that follow -up 
is no longer medically necessary . 
3.5.10  Physical Examinations  
In Part  A, a full physical examination will be performed at Screening and a symptom -directed 
(targeted) physical examination  will be performed at all other scheduled time points indicated 
in the schedule of events ( Table  6-1). The full examination will include assessment of skin, 
head, ears, eyes, nose, throat, neck, thyroid, lungs, heart, cardiovascular, abdomen, lymph 
nodes, and musculoskeletal system/extremities. Interim physical examinations will be 
performed at the discretion of the investigator, if necessary, to evaluate AEs or clinical 
laboratory abnormalities.  Prior to vaccination and at 7 days following va ccination, a physical 
evaluation of the arm that was vaccinated and the associated lymph nodes should be evaluated. 
Height and weight will be measured and body mass index will be calculated at Screening only.  
3.6 Statistical Analysis Plans  
3.6.1 Safety  Endpoints  
The following are the safety (primary) endpoints: 
Part A:  
• Solicited AEs with toxicity scoring (local and systemic reactogenicity events) collected for 
7 days followi ng each vaccination  
• Unsolicited AEs collected for 28 days following each vaccination; addition al classification 
if serious, medically attended, leading to study withdrawal, or an AESI  
• Safety laboratory test results with toxicity scoring ( hematology , serum chemistry, and 
coagulation) collected at B aseline and 7 (+3) days and 28 ( +7) days following each 
vaccination  
• Urinalysis test results with toxicity scoring collected at Baseline and 7 (+3) days following 
each vaccination  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 69 • A subset of safety laboratory test results (as specified in Table  6-1) with toxicity scoring 
collected additionally  at 17 (±3) days following each vaccination and 21 (+3) days  (sentinel 
subjects)  following the first vaccination  
• Vital sign measurements with toxicity scoring on day of vaccination and 7 and 28 days 
following each vaccination 
Part  B: 
• AESIs and S AEs through 1 year (or until resolved, whichever occurs first) following the 
last vaccination  
3.6.2 Immunogenicity Endpoints  
The i mmunogenicity assessments  (cellular and humoral)  are as follows:  
Part A:  
• Neutralizing serum antibody titer s (PRNT50) to Zika (Baseline [pre -vaccination at Visit 1] 
and at 28 days following each vaccination [Visits 4 and 7, respectively])  
• Neutralizing serum antibody titers (PRNT50) to yellow fever (Basel ine [pre-vaccination at 
Visit 1] and at 28 days following each vaccination [Visits 4 and 7, respectively]) in the 
flavivirus- seropositive group  
• T-cell response (cytokine activation to IFN γ or other cytokines) (Baseline [pre -vaccination 
at Visit 1] and at 7 days following  each vaccination [Visits  2 and 5, respectively]) , if results 
of interim immunogenicity analyses  warrant further analyses of samples.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 70 Part B:  
3.6.3 Neutralizing serum antibody tit ers (PRNT50) to Zika virus  at 
168 (±15 ) days and 364 (+15) days (Visits 12 and 19, 
respectively ) following the second vaccination  will be evaluated 
if interim immunogenicity analyses warrants long term analyses 
of persistence. Sample Size Calculations 
Approximately 90 subjects are planned to be randomly assigned to receive study treatment . 
Formal sample size calculations were not performed. The number of subjects was chosen based 
on feasibility and is considered sufficient to meet the study objectives of identifying a dose and 
establishing initial safety results in a  population of healthy adults in a non- endemic Zika region.  
3.6.4 Analysis Sets 
The All Enrolled Subjects set will include subjects who signed the ICF. The All Enrolled 
Subjects set will only be used for descriptive purposes.  
The Safety set will include all sub jects who receive at least 1  dose of study drug ( mRNA -1325 
or placebo).  All subjects in the Safety set will be analyzed according to the study drug actually 
received and not according to the study drug the subject was randomized to receive, in the 
event there is a discrepancy.  
The Per -Protocol set will include all subjects who did not observe a major protocol violation, 
received vaccine within the acceptable vaccination window ( their full dose[ s] of assigned study 
drug), had blood collection within accepted visit windows, and had a pre -vaccination and at 
least 1 serum sample from the post- vaccination testing period available for testing. All subjects 
in the Per -Protocol set will be analyzed according to the study drug the subject was randomized 
to receive and not according to what was actually received, in the event there is a discrepancy. 
In the case where there is not a paired sample for the specific time point that data will not be 
included in the analysis.  
The Intent -to-Treat set will provide supportive analyses. For the Intent -to-Treat set, all subject s 
who were randomized to the study will be included regardless of protocol violations, exceeded 
visit windows, missed vaccination, or missing data.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 71 3.6.5 Statistical Analysis  
Details of all statistical analyses will be described in a statistical analysis plan. All data 
collected will be presented in data listings. Data from subjects excluded from an analysis population will be presented in the data listings but not included in the calculation of summary statistic s. 
Data from subjects who received  placebo will be pooled across cohorts for all  treatments . 
For categorical variables, frequencies and percentages will be presented. Continuous variables will be summarized using descriptive statistics (number of subjects,  mean, median, SD, 
minimum, and maximum).  
3.6.5.1  Immunogenicity  Analys es 
The following immunogenicity outcome measures (for s erum neutralizing antibody titer s) and 
their 95% CIs , where appropriate, will be summarized by treatment group and by visits after 
each va ccination : 
• Geometric mean titer  (GMT) of anti-Zika virus neutralizing antibodies (PRNT50 assay) 
o Part A: A t Baseline (pre -vaccination at Visit 1) and on 28 days after both first and 
second vaccination (Visits 4 and 7, respectively)  
o Part B: At 168 (±15) days and 364 (+15) days (Visits 12 and 19, respectively)  will be 
evaluated if interim immunogenicity analyses  warrants long term analyses of 
persistence.  
• Geometric mean ratio (GMR) Post/Pre  
o Part A and Part B: The ratio of post -vaccination GMT to pre -vaccination ( Visit 1) GMT 
of subjects who have a baseline sample (pre -vaccination at Visit 1) and 
post- vaccination sample at any post -dose time point (Visits  4, 7, 12, or 19; data from 
visits 12 and 19 will be included only if based on interim immunogenicity analyses 
results the evaluation of these later timepoints is warranted. ) 
 
• Seroconversion 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 72 o Part A: The proportion of subjects with Zika virus PRNT50 tit er ≥1:10, ≥ 1:20, ≥ 1:40, 
≥1:80, ≥ 1:160, and ≥ 1:320 at B aseline, Visit 4, and Visit 7  
o Part A: The proportion of subjects with baseline Zika virus PRNT50 tit er <1:10 and 
post- vaccination Zika virus PRNT50 tit er of ≥1:20; or with baseline Zika virus 
PRNT50 tit er ≥1:10 and with post -vaccination 4 -fold titer  increase (Visits  4 or 7) 
o Part B: The proportion of subjects who maintained seroconversion status  at specific 
time points of  168 (±15) days and 364 (+15) days (Visits 1 2 and 19, respectively). Data 
from visits 12 and 19 will be included only if based on interim immunogenicity 
analyses  resu lts the evaluation of these later timepoints is warranted.  
• Cross -Stimulation  with prior flavivirus vaccination (subset of flavivir us-seropositive 
subjects ) 
o Part A:  
o Geometric mean titer  (GMT) of anti -yellow fever neutralizing antibodies at B aseline, 
Visit 4, and Visit 7 
o Geometric mean ratio (Post/Pre) of anti- yellow fever neutralizing antibodies at Visit 4 
and Visit 7  
o The proportion of subjects with anti -yellow fever antibody titer  ≥1:10, ≥ 1:20, ≥ 1:40, 
≥1:80, ≥ 1:160, and ≥ 1:320 at B aseline, Visit 4, and Vi sit 7 
o Additional neutralization assays for other flavivirus may be performed in select subsets  
3.6.5.2  Safety Analyses  
Data from subjects who received  placebo will be pooled across cohorts for all treatments. 
Reactogenicity will be summarized by treatment assignme nt (10-, 25-, or 100-µg mRNA-1325 
or placebo), vaccination (first or second), duration, and severity. Adverse events will be coded 
by preferred term and system organ class using MedDRA  and summarized by part, treatment 
assignment, vaccination (first or second), and overall. Adverse events will also be summarized by severity and relationship to the study vaccine. Descriptive statistics will be presented and 
the difference in the proportion of subjects with AEs will be provided comparing each dose 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 73 level with placebo recipients across all groups. Individual subject listings will be provided for 
all AEs, AEs leading to study withdrawal, AESIs, medically attended AE s, and SAEs. 
Safety data from clinical laboratory  test results and vital sign measurements will be graded by 
severity scoring and analyzed by treatment group and vaccination (first or second). Absolute 
and change from baseline values will be provided according to the toxicity table, along with 
mean, median, and standard deviation. Results of serology, urine drug screen, and pregnancy 
tests will be listed for all subjects randomly assigned to receive study treatment . 
Medical history data for all subjects randomly assigned to receive study treatment  will be 
presented by subject in a listing.  
Baseline demographic and background variables will be summarized by treatment group and 
cohort for all subjects. The number of subjects who enroll in the study and the number and percentage of subjects who complete the study will be presented. Frequency and percentage of subjects who withdraw or discontinue from the study, and the reason for withdrawal or 
discontinuation, will also be summarized.  
Prior and concomitant medication will be listed (with start and stop dates) for each subject and 
summarized by common med ical dictionary coding. Any vaccinations that occur during the 
trial conduct will also be captured and summarized. 
3.6.6 Handling of Missing Data  
For GMT calculation, antibody values reported as below the lower limit of quantification (LLOQ) will be replaced by 0.5 × LLOQ. For fold- rise, values <LLOQ will be replaced by 
0.5 × LLOQ for a numerator and by LLOQ for a denominator. If both the numerator and 
denominator are <LLOQ, then both will be converted in the same way. Values that are greater than the upper limit  of quantification (ULOQ) will be converted to the ULOQ. Missing results 
will not be imputed . 
3.6.7 Interim Analyses  
Following completion of each cohort in Part A, the database will be locked for that cohort and safety and immune test  results will be analyzed th rough 28 days following the second 
vaccination. As dose escalation occurs, cumulative analyses will be included for each subsequent data lock to allow for all prior dosing cohorts to be analyzed by cohort, treatment 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 74 assignment, and in aggregate for mRNA -1325 exposure. Immunogenicity and safety data, 
including mean group analyses of change from Baseline, where applicable, wi ll be summarized 
for each dose  cohort. These data are required to inform decisions on dose selection for this and 
other development prog rams using the same mRNA platform. Subject- level treatment 
assignment will not be released to the subjects or to those individuals involved in managing or 
assessing safety in Part B of the study until that portion of the study is completed . 
Additional information can be found in the statistical analysis plan. 
3.7 Data Quality Assurance  
All aspects of the study will be monitored for compliance with applicable government regulations with respect to current ICH harmonised tripartite guideline E6(R1): Good Clinical  
Practice and current standard operating procedures. The eCRFs will be utilized and accessed 
through iMedidata
® via the internet. This electronic data capture system is validated and 
compliant with US Title 21 of CFR Part 11. Each person involved with the study will have an individual identification code and password that allow for record traceability. There may be an internal quality review audit of the data and additional reviews by the clinical monitor. 
Due to safety review requirements, no more than 3 business days should transpire between 
subject data availability (visits, laboratory  test results, etc) and data entry. As a quality measure, 
timeliness of data entry and data query resolution will be reported to the IST. Other issues of 
data quality that may hinder safety review or pose a concern with patient safety will also be 
reported to the IST with appropriate awareness to the SMC if needed. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 75 4 Investigator Obligations  
The following administrative items are meant to guide the investigator in the conduct of the 
study and may be subject to change based on industry and government standard operating 
procedures, working practice documents, or guidelines. Changes will be repor ted to the IRB 
but will not result in protocol amendments. 
4.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain subject confidentiality. All records will be kept in a secure storage 
area with limited access. Clinical information will not be released without the written 
permission of the subject, except as necessary for monitoring and auditing by the Sponsor , its 
designee, relevant regulatory authority, or the IRB. 
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study, any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose o f the 
study. Prior written agreement from the Sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties. 
4.2 Institutional Review  
Federal regulations and the ICH E6(R1) guidelines require that approval be  obtained from an 
IRB before participation of human subjects in research studies. Before study onset, the protocol, informed consent, advertisements to be used for the recruitment of study subjects, and any 
other written information regarding this study to  be provided to the subject must be approved 
by the IRB. Documentation of all IRB approvals and of the IRB compliance with the ICH 
E6(R1) guidelines will be maintained by the site and will be available for review by the 
Sponsor or its designee. 
All IRB app rovals should be signed by the IRB chairman or designee and must identify the 
IRB name and address, the clinical protocol by title or protocol number or both and the date 
approval or a favorable opinion was granted. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 76 4.3 Subject Consent  
Written informed consent in compliance with US Title 21 CFR Part 50 shall be obtained from 
each subject before he or she enters the study or before any unusual or non -routine procedure 
that involves risk to the subject are performed. If any institution -specific modifications to 
study- related procedures are proposed or made by the site, the consent should be reviewed by 
the Sponsor or its designee or both before IRB submission. Once reviewed, the investigator 
will submit the ICF to the IRB for review and approval before the start of the study. If the ICF is revised during the course of the study, all active participating subjects must sign the revised form.  
Before recruitment and enrollment, each prospective subject will be given a full explanation of the study and be allowed to read the approved ICF. Once the investigator is assured that the subject understands the implications of participating in the study, the subject will be asked to 
give his or her consent to participate in the study by signing the ICF. A separate counseling and  
consent for HIV testing will occur.  
The ICF will also explain that excess serum from immunogenicity testing may be used for 
future research which may be performed at the discretion of the Sponsor to better characterize 
the immune response to the  ZikaV  protein (inclusive of further T - and B -cell responses, 
additional assay development, and the immune response across flaviviruses). 
The investigator or designee will provide a copy of the ICF to the subject. The original form 
shall be maintained in the subject ’s medical records at the site.  
4.4 Study Reporting Requirements  
By participating in this study  the investigator agrees to submit reports of SAEs and AESIs 
according to the time line and method outlined in this protocol. In addition, the investigator agrees to submit annual reports to his or her IRB as appropriate. 
4.5 Financial Disclosure and Obligatio ns 
The investigator is required to provide financial disclosure information to allow the Sponsor to submit the complete and accurate certification or disclosure statements required under 
21 CFR 54. In addition, the investigator must provide to the Sponsor a commitment to 
promptly update this information if any relevant changes occur during the course of the 
investigation and for 1 year following the completion of the study. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 77 Neither the Sponsor , PPD, nor the study site is financially responsible for further testing or 
treatment of any medical condition that may be detected during the screening process. In 
addition, in the absence of specific arrangements, neither the Sponsor, PPD, nor the study site is financially responsible for further treatment of the disease under study.  
4.6 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R1)  8.2 and 
Title 21  of the CFR by providing the following essential documents, including but not limited 
to: 
• IRB approval, 
• An original investigator -signed investigator agreement page of the protocol, 
• Form FDA 1572, fully executed, and all updates o n a new fully executed Form FDA  1572, 
• Curriculum vitae for the principal investigator and each subinvestigator listed on Form 
FDA 15 72. Current licensure must be noted on the curriculum vitae. The curriculum vitae 
will be signed and dated by the principal investigators and subinvestigators at study start -up, 
indicating that they are accurate and current,  
• Financial disclosure informatio n to allow the Sponsor to submit complete and accurate 
certification or disclosure statements required under 21 CFR 54. In addition, the 
investigators must provide to the Sponsor a commitment to promptly update this 
information if any relevant changes occu r during the course of the investigation and for 
1 year aft er the completion of the study, 
• An IRB -approved ICF, samples of site advertisements for recruitment for this study, and 
any other written information about this study that is to be provided to the subject, and 
• Laboratory certifications and reference ranges for any local laboratories used by the site, 
in accordance with 42 CFR 493. 
4.7 Study Conduct  
The investigator agrees that the study will be conducted according to the principles of 
ICH E6(R1). The in vestigator will conduct all aspects of this study in accordance with all 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 78 national, state, and local laws or regulations. The study will be conducted in compliance with 
the protocol, current Good Clinical Practice guidelines – adopting the principles of the  
Declaration of Helsinki – and all applicable regulatory requirements. 
4.8 Data Collection  
4.8.1 Case Report Forms and Source Documents  
As part of the responsibilities assumed by participating in the study, the investigator agrees to 
maintain adequate case histories  for subjects treated as part of the research under this protocol. 
The investigator agrees to maintain accurate eCRFs and source documentation as part of the 
case histories. These source documents may include laboratory reports and similar sources. 
Electro nic case report forms are accessed through iMedidata® via the internet. This electronic 
data capture system is validated and compliant with 21 CFR 11. Each person involved with the 
study will have an individual identification code and password that allows for record 
traceability. Thus, the system, and subsequently any investigative reviews, can identify 
coordinators, investigators, and individuals who have entered or modified records, as well as the time and date of any modifications. There may be internal quality review audit of the data and additional reviews by the clinical monitor.  
Each eCRF is presented as an electronic copy, allowing data entry by site personnel, who can add and edit data, add new subjects, identify and resolve discrepancies, and view records. This system provides immediate direct data transfer to the database, as well as immediate detection of discrepancies, enabling site coordinators to resolve and manage discrepancies in a timely 
manner.  
4.9 Adherence to Protocol  
The investigator agrees to conduct the study as outlined in this protocol in accordance with ICH E6(R1) and all applicable guidelines and regulations. 
4.10 Reporting Adverse Events  
By participating in this study the investigator agrees to submit reports of SAEs according to 
the time line and method outlined in this protocol. In addition, the investigator agrees to submit 
annual reports to his IRB as appropriate. The investigator also agrees to provide the Sponsor 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 79 with an adequate report, if applicable, shortly after completion of the i nvestigator’s 
participation in the study.  
4.11 Investigator’s Final Report  
Upon completion of the study, the investigator, where applicable, should inform the institution; 
the investigator/institution should provide the IRB with a summary of the study’s outcome, 
and the Sponsor and regulatory authority(ies) with any reports requi red. 
4.12 Records Retention  
Essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the study drug . These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirements or by an 
agreement with the Sponsor . It is the Sponsor ’s responsibi lity to inform the 
investigator/institution as to when these documents no longer need to be retained. 
4.13 Publications  
After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the Sponsor will be responsible for 
these activities and will work with the investigators to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and other related issues. The Sponsor has final approval authority over all such issues.  
Data are the property of the Sponsor and cannot be published without their prior authorization, 
but data and publication thereof will not be unduly withheld. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 80 5 Study Management  
5.1 Monitor ing 
5.1.1 Monitoring of the Study  
The clinical monitor, as a representative of the Sponsor , is obligated to follow the study closely. 
In doing so, the monitor will visit the investigator and study facility at periodic intervals, in 
addition to maintaining necess ary telephone and letter contact. The monitor will maintain 
current personal knowledge of the study through observation, review of study records and source documentation, and discussion of the conduct of the study with the investigator and 
staff.  The monit or will be blinded to treatment assignment.  A separate unblinded study monitor 
will be responsible for drug accountability. 
All aspects of the study will be carefully monitored by the Sponsor or its designee for 
compliance with applicable government regulation with respect to current ICH E6(R1) 
guidelines and standard operating procedures. 
5.1.2 Inspection of Records  
The investigator and institution involved in the study will permit study -related monitoring, 
audits, IRB review, and regulatory inspections by providing direct access to all study records. In the event of an audit, the investigator agrees to allow the Sponsor , their representatives, the 
FDA, or other regulatory agency access to all study records. 
The investigator should promptly notify the Sponsor of any audits scheduled by any regulatory 
authorities and promptly forward copies of any audit reports received to the Sponsor. 
5.2 Management of Protocol Amendments and Deviations  
5.2.1 Modification of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, immediate 
hazard to the subject, must be reviewed and approved by the Sponsor or designee. Amendments 
to the protocol must be submitted in writing to the investigator’s IRB for approval before 
subjects are enrolled into an amended protocol. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 81 5.2.2 Protocol Violations and Deviations  
The investigator or designee must document and explain in the subject’s source documentation 
any deviation from the approved protocol. The investigator may implement a deviation from, or a change to, the protocol to eliminate an immediate hazard to study subjects without prior IRB approval. As soon as possible after such an occurrence, the implemented deviation or 
change, the reasons for it, and any proposed protocol amendments should be submitted to the 
IRB for review and approval, to the Sponsor for agreement, and to the regulatory authorities, 
if required.  
A deviation from the protocol is an unintended or unanticipated departure from the procedures 
or processes approved by the Sponsor and the IRB and agreed to by the investigator. Deviations 
usually have an impact on individual subjects or a small group of subjects and do not involve inclusion/exclusion or primary endpoint criteria. A protocol violation occurs when the subject 
or investigator do not adhere to the protocol, resulting in a significant, additional risk to the 
subject. Protocol violations can include non- adherence to inclusion or exclusion criteria, 
enrollment of the subject without prior Sponsor approval, or non- adherence to FDA regulations 
or ICH E6(R1) guidelines. 
Protocol violations and deviations will be documented by the clinical monitor throughout the 
course of monitoring visits. The investigator will be notified in writing by the monitor of violations and deviations. The IRB should be notified of all protocol violations and deviations, if appropriate, in a timely manner. 
5.3 Study Termination  
Although the Sponsor has every intention of completing the study, they reserve the right to 
discontinue it at any time for clinical or administrative r easons.  
The end of the study is defined as the date on which the last subject completes the last visit 
(includes the EOS  visit and any additional long- term follow -up). Any additional long -term 
follow- up that is required to monitor the resolution of a findi ng or AE may be reported through 
an amendment to the clinical study report.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 82 5.4 Final Report  
Whether the study is completed or prematurely terminated, the Sponsor will ensure that clinical 
study reports are prepared and provided to the regulatory agency(ies ) as required by the 
applicable regulatory requirement(s). The Sponsor will also ensure that clinical study reports 
in marketing applications meet the standards of the ICH harmonised tripartite guideline E3: 
Structure and content of clinical study reports. 
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and have the opportunity to 
review complete study results.  
A final clinical study report will contain all data collected through 28 days following the second 
vaccination (Part  A) and all data from the extension safety period through the 12-month 
follow-up after the second vaccination (Part B) of all dosing cohorts.  
 
Upon completion of the clinical study report, the Sponsor will provide the investigator(s) with 
the final approved clinical study report. 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 83 6 Appendices  
6.1 Appendix  1: Schedule s of Events  
The schedule of  events for Part  A is presented in Table  6-1 and the schedule of events for Part  B 
is presented in Table  6-2. 
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 84 Table  6-1 Part A : Schedule of Events  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 85 Procedure  Screening  Treatment Period  
Study visit  0 1 2 3 3aa 4 5 6 7 
Vaccinat ion Day   X    X    
Days relative to most recent vaccination  N/A 0 7 17 21 28 7 17 28 
Window allowance  +28 0 +3 ±3 +3 +7 +3 ±3 +7 
Informed consent  X         
Inclusion/exclusion criteria  X         
Medical history X         
Follicle -stimulating hormone (female subjects only)b X         
Serologyc X         
West Nile virus screen (ONLY if no proof of yellow fever  
vaccination or flavivirus status)d X         
Urine drug screene X X        
Physical examinationf X X X  X X X  X 
Vital sign measurementsg X X/Xc X  X X/Xc  X  X 
Safety laboratory tests Xh Xh Xh Xi Xi Xh Xh Xi Xh 
Urinalysisj X X X   X X   
Pregnancy test (female subjects of childbearing potential)k X X    X    
Randomization   X        
Immune testing (cellular) (PBMC ELISPOT assay)   Xl X    X   
Immune testing (humoral) (PRNT50 neutralization assay)  and 
ZikaV exploratory testing   Xl    Xl   X 
Vaccinationm   X    X    
Reactogenicit y  X/Xc  X  X X/Xc  X   
Provision and instruction on memory aid (and tools provided)n  X    X    
Subject memory aid review : solicited local and systemic AEs, 
oral body temperature, and medications taken    X  X  X   
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 86 Procedure  Screening  Treatment Period  
Study visit  0 1 2 3 3aa 4 5 6 7 
Vaccinat ion Day   X    X    
Days relative to most recent vaccination  N/A 0 7 17 21 28 7 17 28 
Window allowance  +28 0 +3 ±3 +3 +7 +3 ±3 +7 
Subject memory aid review : any unsolicited AEs and related 
medications    X  X X X  X 
Collection of memory aid       X   X 
All unsolicited AEs (including SAEs , medically attended, 
leading to study withdrawal, or AESI )o  X X X X X X X X 
Concomitant medicationsp X X X X X X X X X 
Abbreviations: AE, adverse event; AESI, adverse event of special interest; ELISPOT, enzyme -linked ImmunoSpot; N/A, not applicable; PBMC, peripheral blood 
mononuclear cell; PRNT50, Plaque Reduction Neutralizing Tit er EC50; SAE, serious adverse event.  
Child bearing potential defined as any female who has experienced menarche and who is NOT permanently sterile or post -menopausal. Post -menopausal is defined 
as 12  consecutive months with no menses without an alternative medical cause.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 87 Note: X/Xc  denotes being performed before and after vaccination.  
a Visit 3a will comprise of sentinel cohort only.  
b To confirm post -menopausal status, as needed.  
c Serology testing will include hepatitis B surface antigen, hepatitis C virus antibody, and human immu nodeficiency virus type  1 and 2 antibodies.  
d At Screening , if the subject has no proof of yellow fever vaccination within 20 years, or other documentation of flavivirus status, the West Nile virus screening 
test will be administered.  West Nile virus serology screen can occur up to 90  days prior to randomization.  
e Urine drug screen for drugs of abuse will be performed at Screening and before dose administration at Visit  1 for opiates, cocaine, phencyclidine, 
amphetamines, benzodiazepines, and  methadon e (cannabis excluded). 
f Full physical examination at Screening; symptom -directed (targeted) physical examination at all other scheduled time points. Interim physical examinations 
will be performed at the discretion of the investigator, if necessary. Height and weight will be measured and body mass index calculated at Screening only.  
g Vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature) at Visit  1 and Visit 4 will be collected once 
before dos e administration and at least 60 minutes after dose administration (before subjects are discharged).  
h Safety laboratory test values include   hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular 
volume, platelet count, red blood cell count, total and differential white blood cell count, alanine aminotransfera se, alkaline phosphatase, aspartate 
aminotransferase, amylase, lipase, bilirubin  (total and direct) , blood urea nitrogen, creatinine, random glucose, potassium, sodium, total protein, calcium, 
albumin, prothrombin time, partial thromboplastin time . 
i A subset of safety laboratory test values for albumin, bi lirubin (total and direct), prothrombin time, partial thromboplastin time, alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase.  
j Urinalysis parameters include pH, protein, glucose, ketone, bilirubin, urobilinogen, blood, nitrite, le ucocytes, and specific gravity.  
k A pregnancy test will be performed at Screening (serum pregnancy test), before each dose administration (urine pregnancy test), and as needed at unscheduled 
visits (serum pregnancy test). Serum pregnancy tests will be sen t to the central laboratory, while urine pregnancy tests will be performed by the local laboratory 
on site . 
l To occur prior to vaccination.  
m Vaccination cannot occur if vitals are ≥Grade 2, or if a subject has an intercurrent illness (including a fever).  Each subject will be monitored in the clinic for 
at least 1  hour following vaccination to assess for immediate reactogenicity, with vital sign measurements and local and systemic reacto genicity toxicity 
scored at least 60 minutes  following the vaccination (and earlier if deemed necessary by the investigator).   
n Subjects will be instructed on recording reactogenicity, AEs, and medications (prescription or over -the-counter) on the memory aid (ie, diary card), and will 
be provided measuring tools, and instru cted to call or return to the clinic within 24  hours if a reactogenicity score reaches Grade 3 or greater during the first 
7 days following vaccination.  The site will make a reminder call to the subject during the first 7 days (at approximately Day 4) post-v accination to ensure 
that the memory aid is being completed correctly and consistently . 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 88 o In Part  A of the study, AEs will be assessed from the time of the first dose administration at Visit  1 through Visit  7. However, for the time period after the 
infor med consent form  is signed until before receiving the study drug, AEs will only be recorded when they are defined as one or m ore of the following: 
SAEs, AE s of special interest, or AEs leading to study withdrawal.  
p Concomitant medications include all medi cations (including vaccination outside of trial) taken by the subject from the time of signing the informed consent 
form through 28  days after the second vaccination (Visit  7). 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101  Clinical Study Protocol version 6.0  
 Page 89 Table  6-2 Part B : Schedule of Events  
Procedure 
Study visita 8 9 10 11 12 13 14 15 16 17 18 19 
Study day from 1st dose, if 2nd dose not completed  84 112 140 168 196 224 252 280 308 336 364 392 
Study day from 2nd dose, if completed  56 84 112 140 168 196 224 252 280 308 336 364 
Window allowance  ±7 ±7 ±7 ±7 ±15 ±7 ±7 ±7 ±7 ±7 ±7 + 15 
Safety contact  X X X X X X X X X X X X 
Immun e testing (humoral)  and ZikaV exploratory testingb     X       X 
AESIsc X X X X X X X X X X X X 
SAEsc X X X X X X X X X X X X 
Concomitant medicationsd X X X X X X X X X X X X 
EOS visit             X 
Abbreviations: AESI, adverse event of special interest; EOS, end of study; SAE, serious adverse event.  
a Each safety contact in Part  B will occur by telemedicine (eg, telephone, text  message, internet) and blood samples will be collected as described in footnote  b. 
b      Blood samples for immune persistence will be collected from each subject at 168 (±15) days and 364 (+15) days following the second vaccination.  Immune     
persistence at 168 days and 364 days will be evaluated if interim immunogenicity analyses warrants long term analyses of persistence.  
 
c Each safety contact will capture outcomes of any AESI or SAE that remains unresolved since the last visit or is newly identified through scripted query. 
Additional data may be requested through medically attended visits, and medications and vaccination will be recorded as part of the medical intake for each 
telemedicine visit.  
d Receipt of immunomodulators (including vacc ines), immunosuppressants, or other concomitant medications that could potentially impact immune response 
will be collected through Visit  19. 
 
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 90 6.2 Appendix  2: Adver se Events of Special Interest  
The following is a list of Adverse Events of Special Interest: 
Gastrointestinal disorders: 
• Celiac disease  
• Crohn’s disease 
• Ulcerative colitis  
• Ulcerative proctitis  
Liver disorders: • Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing cholangitis  
Metabolic diseases:  
• Addison’s disease 
• Autoimmune thyroiditis (including Hashimoto thyroiditis)  
• Diabetes mellitus type I  
• Grave's or Basedow’s disease  
Musculoskeletal disorders: • Antisynthetase syndrome 
• Dermatomyositis  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 91 • Juvenile chronic arthritis (including Still’s disease)  
• Mixed connective tissue disorder 
• Polymyalgia rheumatic  
• Polymyositis  
• Psoriatic arthropathy  
• Relapsing polychondritis 
• Rheumatoid arthritis  
• Scleroderma, including diffuse systemic form and CREST syndrome 
• Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter's Syndrome) 
and undifferentiated spondyloarthritis 
• Systemic lupus erythematosus  
• Systemic sclerosis  
Neuro -inflammatory disorders: 
• Acute disseminated encephalomyelitis, including site specific variants (eg,  non-infectious 
encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis)  
• Cranial nerve disorders, including paralyses/paresis (eg, Bell’s palsy) 
• Guillain -Barré syndrome, including Miller Fisher syndrome and other variants 
• Immune- mediated peripheral neuropathies and plexopathies, including chronic 
inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy 
• Multiple sclerosis  
• Narcolepsy  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 92 • Optic neuritis  
• Transverse myelitis  
Skin disorders: 
• Alopecia areata  
• Autoimmune bullous skin diseases, including pemphigus, pemphigoid, and dermatitis 
herpetiformis  
• Cutaneous lupus erythematosus 
• Erythema nodosum 
• Morphoea 
• Lichen planus 
• Psoriasis 
• Sweet’s syndrome 
• Vitiligo  
Vasculitides: • Large vessels vasculitis including: including Takayasu's arteritis and giant cell 
arteritis/temporal arteritis  
• Medium sized and/or small vessels vasculitis including: polyarte ritis nodosa, Kawasaki's 
disease, microscopic polyangiitis, Wegener's granulomatosis, Churg−Strauss syndrome (allergic granulomatous angiitis), Buerger’s disease (thromboangiitis obliterans), 
necrotizing vasculitis and anti -neutrophil cytoplasmic antibody positive vasculitis (type 
unspecified), Henoch−Schönlein purpura, Behcet's syndrome, and leukocytoclastic 
vasculitis  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 93 Others:  
• Antiphospholipid syndrome 
• Autoimmune hemolytic anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly 
progressive, membranous glomerulonephritis, membranoproliferative glomerulonephritis, 
and mesangioproliferative glomerulonephritis)  
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia 
• Goodpasture syndrome 
• Idiopathic pulmonary fibrosis 
• Pernicious anemia  
• Raynaud’s phenomenon 
• Sarcoidosis 
• Sjögren’s syndrome  
• Stevens -Johnson syndrome 
• Uveitis  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 94 6.3 Appendix 3: Toxicity Grading Scale Tables  
The toxicity grading scales for clinical and laboratory abnormalities are presented in Table  6-3 
and Table  6-4, respectively. Note that for laboratory abnormalities, grading only occurs if the 
values reside outside of the normal values established by the clinical laboratory. For study -
specific laboratory normal ranges and associated toxicity grades, refer to the laboratory manual.  
Tabl e 6-3 Tables for Clinical Abnormalities  
Local Reaction to Injectable 
Product  Mild  
(Grade 1)  Moderate  
(Grade  2) Severe 
(Grade  3) Potentially 
Life 
Threatening  
(Grade 4)  
Pain  Does not 
interfere with 
activity  Repeated use of 
non-narcotic 
pain reliever 
> 24 hours or 
interferes with 
activity  Any use of 
narcotic pain 
reliever or 
prevents daily 
activity  ER visit or 
hospitalization  
Tenderness  Mild discomfort 
to touch  Discomfort 
with movement  Significant  
discomfort  at 
rest ER visit or 
hospitalization  
Erythema/Redness  * 2.5 – 5 cm  5.1 – 10 cm  > 10 cm  Necrosis or 
exfoliative 
dermatitis  
Induration/Swelling **  2.5 – 5 cm and 
does not 
interfere with 
activity  5.1 – 10 cm or 
interferes with 
activity  > 10 cm or 
prevents daily 
activity  Necrosis  
Abbreviation: ER, emergency room.  
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should be 
recorded as a continuous variable.  
** Induration/swelling should be evaluated and graded using the functional scale as well as the actual 
measurement.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for clinical abnormalities ( CBER 2007).  
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 95 Vital Signs *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Tachycardia (beats per 
minute)  101 – 115 116 – 130 > 130  ER visit or 
hospitalization 
for arrhythmia  
Bradycardia (beats per 
minute)**  50 – 54 45 – 49 < 45 ER visit or 
hospitalization 
for arrhythmia  
Hypertension (systolic) (mm  Hg) 141 – 150 151 – 155 > 155  ER visit or 
hospitalization 
for malignant 
hypertension 
Hypertension (diastolic) (mm  Hg) 91 – 95 96 – 100 > 100  ER visit or 
hospitalization 
for malignant 
hypertension 
Hypotension (systolic) (mm  Hg)  85 – 89 80 – 84 < 80 ER visit or 
hospitalization 
for hypotensive 
shock  
Respiratory rate (breaths per minute)  17 – 20 21 – 25 > 25 Intubation  
Abbreviation: ER, emergency room.  
Note that fever is classified under systemic reactions for grading purposes.  
* Subject should be at rest for all vital sign measurements.  
** When resting heart rate is between 60 – 100 beats per minute. Use clinical judgment when characterizing 
bradycardia among some health y subject populations, for example, conditioned athletes.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for clinical abnormalities ( CBER 2007).  
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 96 Systemic (General)  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Fever (°C) *  
(°F) *  38.0 – 38.4 
100.4 – 101.1  38.5 – 38.9 
101.2 – 102.0  39.0 – 40 
102.1 – 104 > 40 
> 104  
Nausea/vomiting  No interference 
with activity or 1 to 
2 episodes/ 
24 hours  Some interference 
with activity or 
> 2 episodes/ 
24 hours  Prevents daily 
activity, requires 
outpatient IV 
hydration ER visit or 
hospitalization 
for hypotensive 
shock  
Diarrhea  2 – 3 loose stools 
or < 400 g/ 
24 hours  4 – 5 stools or 400 
– 800 g/ 24 hours  6 or more watery 
stools or 
> 800 g/ 
24 hours or 
requires 
outpatient IV 
hydration ER visit or 
hospitalization  
Headache  No interference 
with activity  Repeated use of 
non-narcotic pain 
reliever > 24 hours 
or some 
interference with 
activity  Significant; any 
use of narcotic 
pain reliever or 
prevents daily 
activity  ER visit or 
hospitalization  
Fatigue/Malaise  
(unusual tiredness)  No interference 
with activity  Some interference 
with activity  Significant; 
prevents daily 
activity  ER visit or 
hospitalization  
Generalized myalgia 
(muscle ache or pain)  No interference 
with activity  Some interference 
with activity  Significant; 
prevents daily 
activity  ER visit or 
hospitalization  
Generalized arthralgia 
(joint ache or pain)  No interference 
with activity  Some interference 
with activity not 
requiring medical 
intervention  Prevents daily 
activity and 
requires medical 
intervention  ER visit or 
hospitalization  
Abbreviations: ER, emergency room; IV , intravenous.  
* Oral temperature; no recent ho t or cold beverages or smoking.  
Source s: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for clinical abnormalities ( CBER 2007).  DAIDS Grading the 
Severity of Adult and Pediatric Adverse Events ( DAIDS 20 14). 
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 97 Table  6-4 Tables for Laboratory Abnormalities 
Serum Chemistry*  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Gra de 4)**  
Sodium – hyponatremia (mEq/L)  132 – 134 130 – 131 125 – 129 < 125  
Sodium – hypernatremia (mEq/L)  144 – 145 146 – 147 148 – 150 > 150  
Potassium – hyperkalemia (mEq/L)  5.1 – 5.2 5.3 – 5.4 5.5 – 5.6 > 5.6  
Potassium – hypokalemia (mEq/L)  3.5 – 3.6 3.3 – 3.4 3.1 – 3.2 < 3.1  
Glucose – hypoglycemia (mg/dL)  65 – 69 55 – 64 45 – 54 < 45 
Glucose – hyperglycemia  
Random (mg/dL)   
110 – 125  
126 – 200  
> 200 Insulin requirements or 
hyperosmolar coma  
Blood urea nitrogen (mg/dL)  23 – 26 27 – 31 > 31 Requires dialysis  
Creatinine (mg/dL)  1.5 – 1.7 1.8 – 2.0 2.1 – 2.5 > 2.5 or requires 
dialysis  
Calcium – hypocalcemia (mg/dL)  8.0 – 8.4 7.5 – 7.9 7.0 – 7.4 < 7.0  
Calcium – hypercalcemia (mg/dL)  10.5 – 11.0 11.1 – 11.5 11.6 – 12.0 > 12.0  
Albumin – hypoalbuminemia 
(g/dL)  2.8 – 3.1 2.5 – 2.7 < 2.5  – 
Total Protein – hypoproteinemia 
(g/dL)  5.5 – 6.0 5.0 – 5.4 < 5.0  – 
Alkaline phosphate; increase by 
factor  1.1 – 2.0 × 
ULN  2.1 – 3.0 × 
ULN  3.1 – 10 × 
ULN  > 10 × ULN 
Liver function tests – ALT and 
AST; increase by factor  1.1 – 2.5 x 
ULN  2.6 – 5.0 × 
ULN  5.1 – 10 × 
ULN  > 10 × ULN 
Bilirubin – when accompanied by 
any increase in liver function test; increase by factor  1.1 – 1.25 × 
ULN  1.26 – 1.5 × 
ULN  1.51 – 1.75 
× ULN  > 1.75 × ULN  
Bilirubin – when liver function test 
is normal; increase by factor  1.1 – 1.5 × 
ULN  1.6 – 2.0 × 
ULN  2.0 – 3.0 × 
ULN  > 3.0 × ULN 
Pancreatic enzymes – amylase and 
lipase  1.1 – 1.5 × 
ULN  1.6 – 2.0 × 
ULN  2.1 – 5.0 × 
ULN  > 5.0 × ULN 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of the normal 
range.  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional no rmal reference ranges should be provided to demonstrate that they are appropriate.  
** The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of 
the laboratory abnormalities as potentially life threatening ( Grade 4). For example, a low sodium value that 
falls within a Grade 3 parameter (125 – 129 mE/L) should be recorded as a Grade 4 hyponatremia event if 
the subject had a new seizure associated with the low sodium value.  
Source: Guidance for industry – Toxic ity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for laboratory abnormalities ( CBER 2007).  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 98 Hematology *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Hemoglobin (female) 
(g/dL)  11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 < 8.0  
Hemoglobin (female) change from baseline 
value (g/dL)  Any decrease – 
1.5 1.6 – 2.0 2.1 – 5.0 > 5.0  
Hemoglobin (male) (g/dL)  12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 < 8.5  
Hemoglobin (male) 
change from baseline 
value (g/dL)  Any decrease – 
1.5 1.6 – 2.0 2.1 – 5.0 > 5.0  
WBC increase (cell/mm3) 10800 – 15000  15001 – 20000  20001 – 25000  > 25000  
WBC decrease (cell/mm3) 2500 – 3500  1500 – 2499  1000 – 1499  < 1000  
Lymphocytes decrease 
(cell/mm3) 750 – 1000  500 – 749 250 – 499 < 250  
Neutrophils decrease 
(cell/mm3) 1500 – 2000  1000 – 1499  500 – 999 < 500  
Eosinophils (cell/mm3) 650 – 1500  1501 – 5000  > 5000  Hypereosinophilic  
Platelets decreased 
(cell/mm3) 125 000 – 
140 000 100 000 – 
124 000 25000 – 99000  < 25000  
PT; increase by factor  1.0 – 1.10 × ULN  1.11 – 1.20 × 
ULN  1.21 – 1.25 × 
ULN  > 1.25 × ULN  
PTT; increase by factor  1.0 – 1.2 × ULN  1.21 – 1.4 × ULN  1.41 – 1.5 × ULN  > 1.5 × ULN 
Abbreviations: PT, prothrombin time; PTT, partial thromboplastin time; ULN, upper limit of normal; WBC, white 
blood cell.  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables for laboratory abnormalities  (CBER 2007).  
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 99 Urine *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Protein  Trace  1+ 2+ Hospitalization or 
dialysis  
Glucose  Trace  1+ 2+ Hospitalization 
for 
hyperglycemia  
Blood (microscopic) – 
red blood cells per high 
power field (rbc/hpf)  1 – 10 11 – 50 > 50 and/or gross 
blood  Hospitalization or 
packed red blood 
cells transfusion  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Source: Guidance for industry – Toxicity grading scale for heathy adult and adolescent volunteers enrolled in 
preventative vaccine clinical trials; Tables fo r laboratory abnormalities ( CBER 2007).  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 100 6.4 Appendix 4: World Health Organization Zika  Situation Report  as of February 2017 
 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 101 The WHO map (dated 01 February 2017; WHO 2017) showing Zika -endemic regions is subject to routine updating . The most up- to-date 
regions can be found within each situation report, including the countries and territories listing Zika virus transmission (WHO Table 1 
below ; WHO 2017) at : http://www.who.int/emergencies/zika -virus/situation -report/en/ 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 102  
PPD will operationalize the monitoring of the Zika -endemic changes and notify a site if they 
appear to be reaching the endemic listing.  
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 103 7 Reference List  
Akahata W, Yang ZY , Andersen H, et al. A virus- like particle vaccine for epidemic Zika  virus 
protects nonhuman primates against infection. Nat Med. 2010;16(3):334-8. 
Bahl K, Senn JJ, Yuzha kov O, et al. Preclinical and clinical demonstration of 
immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 
[Internet] 2017 Apr 27 [cited 2017 May 17]. Available from 
http://dx.doi.org/10.1016/j.ymthe.2017.03.035. 
Brandler S,  Ruffi é C, Combredet C, et al. A recombinant measles vaccine expressing 
chikungunya virus- like particles is strongly immunogenic and protects mice from lethal 
challenge with chikungunya virus. Vaccine. 2013;31:3718-25. Brann, J. Zika Virus & Pregnancy News [Internet]. CDC raises alert level to “highest” over 
Zika o utbreak. 2016 Feb 09. [cited 2016 09 21]. Available from: 
http://www.zikaviruspregnancy.com/news/55-breakingzikanews/129- cdcraisesalertlevel  
Brasil, P, Pereira JP Jr, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro - preliminary report.  N Engl J Med. 2016;375:2321-34. 
Coelho T, Adams, D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin 
amyloidosis. N Engl J Med. 2013;369(9):819-29. 
Darwin JR, Kenney JL, Weaver, SC. Transmission potential of two chimeric chikungunya 
vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. Albopictus. Am J Trop Med Hyg. 2011;85(6):1012-5. 
Department of Health and Human Services  (DHHS) , Food and Drug Administration, Center 
for Biologics Evaluation and Research  (CBER)  (US). Guidance for industry: Toxicity 
grading scale for healthy volunteers enrolled in preventative vaccine clinical trials . 
September 2007 [cited 2016 Aug 17] [10  screens]. Available from: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInf
ormation/Guidances/Vaccines/ucm091977.pdf. 
Department of Health and Human Services  (DHHS) , National Institutes of Health, National 
Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) 
Document Number: VV-CLIN-000234 eDMS Version: 2.0
Moderna Therapeutics , Inc. mRNA -1325  
Protocol mRNA -1325- P101   Clinical Study Protocol version 6.0  
 Page 104 table for grading the s everity of adult and pediatric a dverse events, Version 2.0. November 
2014. [cited  2016 Sep  15] [21 screens] Available from: 
rsc.tech -res.com/Document/safetyandpharmacovigilance/DAIDS_AE_Grading_Table_v2_N
OV2014.pdf. 
Franca RF, Neves MH, Ayres CF, et al. First international workshop on Zika virus held by 
Oswaldo Cruz Foundation FIOCRUZ in northeast Brazil March 2016 - a meeting report. 
PLoS Negl Trop Dis. 2016;10(6):e0004760. 
Jayaram an M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid 
nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 
2012;51(34):8529-33. 
Larocca RA , Abbink P, Peron JP, et al. Vacci ne protection against Zika virus from Brazil. 
Nature. 2016;536(7617):474-8. Mui BL, Tam YK, Jayaraman M, et al. Influence of polyethylene glycol lipid desorption rates 
on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic 
Acids. 2013;2:e139. 
Wang E, V olkova E, Adams A, et al. Chimeric alphavirus vaccine candidates for 
chikungunya. Vaccine.  2008;26(39):5030-9. 
World Health Organization  [Internet]. Zika  virus outbreak global response. 2016a Jul 15 
[cited 2016 Aug 17]; [1 scre en]. Available from: 
http://www.who.int/emergencies/zika -virus/response/en/ 
World Health Organization [Internet]. Situation Report. Zika Virus. 2017 Feb 02 
[cited  2017 Feb  16]; [ 6 screens]. Available from: 
http://apps.who.int/iris/bitstream/10665/254507/1/zikasitrep2Feb17- eng.pdf?ua=1  
Document Number: VV-CLIN-000234 eDMS Version: 2.0